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Abstract: In this review article, yeast model-based research advances regarding the role of Amyloid-β
(Aβ), Tau and frameshift Ubiquitin UBB+1 in Alzheimer’s disease (AD) are discussed. Despite having
limitations with regard to intercellular and cognitive AD aspects, these models have clearly shown
their added value as complementary models for the study of the molecular aspects of these proteins,
including their interplay with AD-related cellular processes such as mitochondrial dysfunction
and altered proteostasis. Moreover, these yeast models have also shown their importance in
translational research, e.g., in compound screenings and for AD diagnostics development. In addition
to well-established Saccharomyces cerevisiaemodels, new upcoming Schizosaccharomyces pombe, Candida
glabrata and Kluyveromyces lactis yeast models for Aβ and Tau are briefly described. Finally, traditional
and more innovative research methodologies, e.g., for studying protein oligomerization/aggregation,
are highlighted.
Keywords: Alzheimer’s disease; yeast; Tau; amyloidβ; ubiquitin; aggregation; oligomerization; prion
1. Introduction
1.1. Alzheimer’s Disease (AD)
Alzheimer’s disease (AD) is the most common neurodegenerative disease worldwide. It accounts
for approximately 60–70% of all dementia cases and affects about 6% of the population aged
over 65 (late-onset AD), whereas 2–10% of patients suffer from early-onset AD [1,2]. Currently,
around 50 million individuals live with this devastating chronic disease and it has been estimated
that the number will increase up to approximately 106 million people by 2050 due to an increasing
aging population [2,3]. At the cellular level, AD is characterized by an irreversible and progressive
loss of neuronal structure and function within certain regions of the brain including the hippocampus
and neocortical brain, leading to cognitive dysfunction and dementia [4]. Widespread experimental
evidence also suggests that AD is characterized by synaptic dysfunction early on in the disease process,
disrupting communication within neural circuits important for memory formation and other cognitive
functions such as intellectuality and comprehensive capacity [5–7].
Therefore, damage to these brain structures results in memory loss, language difficulties and
learning deficits that are typically observed within early stages of clinical manifestation of AD.
In addition, upon disease progression, a decline in other cognitive domains occurs which will result
in the complete inability to function independently in basic daily activities [7]. Besides AD having
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a profound impact on the life quality of patients, this chronic disease also imposes a huge economic
burden on healthcare systems globally with an associated cost which is estimated will exceed $1 trillion
by 2050 [8].
The neuronal damage is related to the accumulation of misfolded proteins into extracellular and
intracellular aggregates, consisting of Aβ peptides or protein Tau, respectively [9,10]. It is not yet
clear whether the presence of these two hallmarks is the cause of AD or mainly the result of a cascade
of cellular events including oxidative stress, mitochondrial dysfunction and apoptosis. Either way,
the exact mechanism by which these proteins damage neurons is still unknown.
1.2. Yeast as a Model Organism to Study AD: Advantages
Studies to gain more insights on AD primarily make use of human cell lines and transgenic mouse
models. However, yeast cell models are playing an increasingly important role in unravelling the
fundamental disease aspects of AD. In fact, the yeast S. cerevisiae is a very widely studied single-celled
model organism. With more than 6000 genes distributed on 16 chromosomes, its genome was the first
eukaryotic genome to be completely sequenced in 1996 [11]. Since then, it has been estimated that
nearly 31% of yeast genes have human orthologues [12]. Beyond the laboratory yeast strains, many
different natural, brewery and clinical isolates exist and all have a core genome of about 5000 shared
genes [12]. Yeast reproduction is through mitosis of either a haploid or a diploid cell. Haploids are of
2 different mating type (a or α) and a haploid cell can only mate with a cell of the opposite mating
type. Mating leads to the formation of a diploid cell that can either continue to exist and bud as
a diploid or, under conditions of stress, produce spores by meiosis. Spores can then later give rise
to haploid cells [12]. Haploidy implies that gene-knockout strains can easily be obtained. In 2001,
a collection of isogenic yeast strains, each deleted for one of the 6000 putative open reading frames
(ORFs), was created [12]. This allowed for the easy phenotypic analysis of mutants, paving the way
to determining gene function. In addition, yeast cells share many conserved biological processes
such as cell cycle progression, protein turnover, vesicular trafficking and signal transduction with
cells of higher eukaryotes [13], including human neurons. Its short generation time (1.5 h on rich
medium), means that it can be very easily cultured. Thanks to its susceptibility to simple genetic and
environmental manipulations, this model organism has become a valuable tool to shed more light on
the complex and fundamental intracellular mechanisms underlying neurodegenerative diseases.
So-called “humanized yeast model systems” have been constructed and used as a tool to
investigate the molecular mechanisms involved in several neurological disorders [14,15]. The main
advantage of using yeast is its reduced complexity compared to the mammalian models. On the
contrary, Tau and Aβ have no functional yeast orthologues. Heterologous expression of Tau and Aβ
can be highly informative and provides useful new insights into the pathobiology of these proteins
in vivo. At the same time, yeast is an excellent screening tool for compounds that may be useful in
treatment and/or prevention of AD.
1.3. Yeast as a Model Organism to Study AD: Limitations
Despite being a powerful and simplified model system, yeast also has its natural limitations.
As a unicellular organism, the most important limitation for neurodegenerative disease research
is the analysis of disease aspects that focus on multicellularity and cell–cell interactions.
These interactions include synaptic transmissions, axonal transport, glial-neuronal interactions,
immune and inflammatory responses and many neuronal specializations that are likely to play
an important role in neurodegeneration, but cannot be recapitulated in yeast [16]. Moreover, it is also
impossible to study the cognitive aspects of AD in yeast cells.
This review discusses the findings of more recent studies on neurodegenerative disorders
conducted using different yeast species.
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2. Humanized Yeast Models to Study Tau Biology
2.1. Protein Tau: Structure, Functions and Modifications
Protein Tau, encoded by the 16 exon long microtubule (MT)-associated protein Tau (MAPT) gene
located on chromosome 17q21.31, is present in neuronal and glial axons, but has also been detected
outside of cells [17–22]. Tau is natively unfolded and has the tendency to adapt a paperclip-like
shape, in which the N- and C-terminal domains and repeat regions are all closely located to each
other (see below) [23]. It is a MT associated protein, susceptive to dynamic (de-) phosphorylation.
These modifications influence its main cellular function which consists of regulating MT dynamic
instability i.e., the process of polymerization (rescue) and depolymerization (catastrophe) [24–27].
Besides being involved in the regulation of MT dynamics, Tau has functions in regulating axonal
transport/elongation/maturation, synaptic plasticity andmaintaining DNA and RNA integrity [28–37].
It is clear that Tau is involved in numerous processes and that loss of Tau function can initiate
neurotoxicity through disruption of various processes in which it is involved. For a more complete
overview of physiological and pathological Tau functions, we refer to [38].
A first mechanism by which Tau function is regulated is alternative splicing. Due to alternative
splicing of exon 2, 3 and 10 of the MAPT gene, Tau can be present in 6 different isoforms differing
in the number of N-terminal inserts (1 or 2) and conserved 18 amino acid long repeats (3 to 4)
in the MT binding region (C-terminal region or assembly domain) [39,40]. Tau isoforms with 4
repeat regions show a stronger interaction with MT and are more efficient in MT assembly [41–43].
The N-terminal projection region of the protein is located adjacent to a proline rich region and
has a role in MT spacing and stabilization [44,45]. In addition, it was proposed that this domain,
which projects away fromMT, interacts with cell organelles such as the plasmamembrane, mitochondria
and actin filaments [46–51]. This binding could be facilitated via an interaction between the PXXP
motifs in the proline-rich region and the SH3 domains of the src-family non-receptor tyrosine kinases
(e.g., kinase FYN) [52–54]. Note that this plasma membrane interaction might play an important role
in vesicle-mediated secretion and therefore impact the cell-to-cell spreading of protein Tau. It was
proposed that the Tau-FYN interaction may regulate the post-synaptic targeting of FYN, and thereby
mediate Aβ-induced excitotoxicity [23]. Additional proposed pathways for cell-to-cell transfer are
tunneling nanotubes and trans-synaptic spreading [55–58]. This spreading process is still ill-defined
and it still needs to be proven if spreading of (a) toxic Tau species is sufficient or necessary for the
induction of a tauopathy. Guo and colleague published a comprehensive article on this emerging field
within Tau biology [59]. Finally, the proline-rich domain of Tau has a role in facilitating the binding of
the MT binding region to the MT [60,61].
Tau function is also regulated by several post-translational modifications including
phosphorylation, glycosylation, truncation, nitration, isomerisation, acetylation, glycation,
ubiquitination, deamidation, methylation, sumoylation and oxidation [38]. Tau phosphorylation has
been studied extensively. The protein contains 80 putative serine/threonine and 5 potential tyrosine
phosphorylation sites, of which the majority is phosphorylated in vitro, on the 2N/4R (2 N-terminal
inserts and 4 amino acid repeat regions) isoform. Tau is phosphorylated by numerous kinases,
grouped in 4 different classes [62,63]. More recently, GSK3α, GSK3β, MAPK13 and AMP-activated
protein kinase were found to play an actual role in in vivo Tau phosphorylation using different cell
lines [64,65]. Tau (de-) phosphorylation is an important factor influencing Tau’s affinity for MT, thereby
regulating its role in MT (de-) polymerization. On the other hand, aberrant phosphorylation (so-called
hyperphosphorylation) on several epitopes (e.g., Thr181, Thr231, Ser202, Ser205, Ser214, Ser396, Ser404,
Ser409, and Ser422), which severely affects Tau’s MT binding capacity and stabilizing properties [66–68]
can lead to an increased propensity of Tau to subsequently oligomerize and aggregate into paired
helical filaments (PHF) and neurofibrillary tangles (NFT) [66]. These NFT are characteristic for a group
of neurodegenerative diseases called tauopathies including AD.
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The aggregation is due to a redistribution of mainly MT bound to unbound Tau, which facilitates
Tau-Tau interactions made possible by 2 hexapeptide motives in repeat regions 2 and 3, which can
adapt β-sheet structures [69]. While the repeat domain makes up the PHF core, the N- and C-terminal
Tau region form a “coat” around this core [23].
Hyperphosphorylation can also induce pathology through other mechanisms. It can first of
all lead to Tau missorting from axons to the somatodendritic compartment, which might cause
synaptic dysfunction. Another consequence is affected substrate recognition, which leads to an altered
proteasomal degradation [70].
Phosphorylation is, however, only one potential covalent modification Tau can undergo and it
should be noted that this modification alone is not sufficient to cause aggregation. Phosphorylation at
some sites (e.g., Ser214 and Ser262) in the repeat domain can even protect against aggregation [69].
Thus, it is suggested that phosphorylation might facilitate this process, and therefore serves as
an indirect aggregation inducer, and that other factors are involved as well. Indeed, other modifications,
and especially truncation, can be equally important for disease development. Tau truncated at
Glu391 and Asp421, for example, has been identified as an event following phosphorylation and
facilitating Tau filament formation. Tau truncation can even induce neurodegeneration independently
of Tau aggregation through the formation of specific Tau fragments [69]. Tau truncation disrupts
the paperclip-like structure, thereby promoting Tau aggregation. Tau ubiquitination, on the
other hand, is considered a protective strategy of the cell to get rid of toxic Tau intermediates
and accumulations of hyperphosphorylated Tau are mainly found in cells with a defective or
malfunctioning ubiquitin/proteasome system. The latter can be caused by oxidative stress due
to mitochondrial malfunctioning, illustrating the complex cellular pathways involved in the induction
of Tau-mediated toxicity. For a more complete overview of Tau post-translational modifications and
their consequences on Tau pathology, we refer to [38,71].
The Tau aggregation process itself seems to be a requirement for Tau-induced toxicity and
although recent papers are pointing towards the soluble mono- or oligomeric hyperphosphorylated
Tau species as being the toxic Tau forms, their relative contribution remains largely unclear.
The insoluble aggregated structures are thought to act as protective structures by sequestering the
toxic species [72–76].
Numerous Tau mutations, either causing AD or other tauopathies such as frontotemporal
dementia and parkinsonism linked to chromosome 17 (FTDP-17), have been documented over the
years and can either be missense, silent or causing a deletion. Depending on the mutation’s nature and
its gene location, the mutation can directly disturb Tau’s MT binding capacity, thereby increasing Tau’s
tendency for aggregation, or indirectly by affecting the 4R:3R ratio by influencing Tau splicing [77–85].
Most of these mutations are nicely documented on the “Alzforum” website.
2.2. From Complementary Disease Models to AD Diagnostics
Historically, the AD field has been dominated by research supporting Aβ having the main role in
pathogenesis. Only after the discovery of severalMAPTmutations in FTDP-17 did Tau research receive
a significant and rightful boost. Indeed, both in vitro and in vivo studies show evidence that Tau is
required for Aβ-mediated neurotoxicity [86]. Therefore, only a limited amount of research articles on
the pathological aspects of protein Tau using the yeast S. cerevisiae as a model organism have been
published to date [87–89].
Figure 1 gives a visual overview of human Tau processes and modifications in S. cerevisiae.
These studies have already been extensively reviewed, so a brief summary will be given.
Upon overexpression in S. cerevisiae, Tau becomes hyperphosphorylated and acquires several
pathological phospho-epitopes (AD2 (p-Ser396/p-Ser404), AT8 (p-Ser202/p-Ser205), AT270 (p-Thr181),
AT180 (p-Thr231/p-Ser235) AT100 (p-Thr212/p-Ser214) and PG5 (p-Ser409)). Moreover, it was possible
to detect the disease-relevant conformational epitope recognized by the MC1 antibody.




Figure 1. Humanized yeast model expressing human protein Tau: overview of Tau processes and
modifications in S. cerevisiae. Double arrows indicate a bidirectional/reversible reaction and dashed
lines specify the promoter and expressed human Tau gene on the plasmid. ‘TPI’; Triosephosphate
isomerase promoter, ‘P’; phosphate group.
Pho85 and Mds1 protein kinases, yeast orthologues of human Tau kinases Cdk5 and GSK3β,
respectively, were shown to play a key role in modulating Tau phosphorylation. It was suggested that
Pho85 may have a direct or indirect inhibitory effect on the activity of Mds1. Upon deletion of Pho85,
phosphorylation of Tau was enriched on the AD2 and PG5 epitopes. Accordingly, the MC1-reactive
Tau fraction was also higher. Tau aggregation in this pho85∆ strain was assessed by measuring the
sarkosyl-insoluble Tau (SinT) fraction and it was proposed that Tau epitopes PG5 and AT100 might play
a crucial role in the accumulation of SinT aggregates, since these epitopes were especially enriched in
the insoluble fraction [87]. The importance of phosphorylation of the PG5 epitope for Tau aggregation
was also confirmed in a follow-up study in which aggregation of several Tau mutants was assessed.
In addition, PG5 epitope phosphorylation is detrimental for Tau’s MAPT function, illustrated by lack
of Tau binding to taxol-stabilized MT from porcine Tubulin in vitro [88,89].
Despite all of this, Tau 2N/4R and 2N/3R expression does not induce an impaired growth
phenotype in S. cerevisiae [87,88,90]. The latter is not necessarily expected since little attention was
paid to the extent of formation of early stage, presumably toxic, soluble (oligomeric) Tau species in
these studies. The possibility exists that these oligomeric Tau species are rapidly sequestered in inert
aggregates as a cell protection mechanism.
As described above, several other post-translational modifications are expected to contribute
to tauopathy development, besides phosphorylation. Therefore, it might be highly interesting to
verify if these modifications are also recapitulated in yeast, and if so, to what extend they could offer
an explanation for the (lack of) aggregation/toxicity in yeast cells.
On top of that, it was found that oxidative stress and mitochondrial dysfunction, independently
of Tau phosphorylation, also strongly induce Tau aggregation in yeast cells [88]. It is also worth
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mentioning that inducing oxidative stress resulted in Tau dephosphorylation, in accordance with
other results obtained from human, rat and mice neuronal cells [91,92]. One potential mechanism
is oxidative stress-induced Pin1 activation. Pin1, a peptidyl prolyl cis/trans isomerase, can then
subsequently activate Phosphatase 2a. De Vos and colleagues reported, in accordance with this finding,
that a dysfunctional Ess1, Pin1’s yeast orthologue, increases Tau hyperphosphorylation [93].
On the other hand, other studies point out that oxidative stress does not alter Tau phosphorylation
or even induces Tau hyperphosphorylation. These studies were performed using a Dropsophila
melanogaster model and human neuronal cells [94], respectively. The interplay between oxidative
stress and Tau phosphorylation, therefore, needs more attention in future studies to further elucidate
their relationship.
Tau was also purified, using anion-exchange chromatography, from the previously mentioned
pho85∆ S. cerevisiae strain, maintaining its hyperphosphorylated MC1-reactive state, and could
subsequently seed aggregation of wt 2N/4R Tau protein purified from a wt strain in vitro [87].
The possibility of purifying these stable, pathologically-relevant, Tau structures from S. cerevisiae
cells paved the way for using yeast-purified Tau as an antigen source for mice immunization [95]. This
strategy offers a significant benefit over E. coli based Tau purifications and antibody generation [76,96,
97], since Tau is not post-translationally modified in bacterial cells.
Although oligomerization can be induced by use of, for example, arachidonic acid or heparin,
there is no evidence that these artificially formed oligomers/aggregates are the actual toxic species
and, therefore, that the produced monoclonal antibodies recognize pathologically relevant Tau species.
ADx215, an antibody developed by immunizing mice with 2N/4R Tau purified from a pho85∆
S. cerevisiae strain, is capable of detecting both mono- and oligomeric Tau protein [95]. This antibody
was recently successfully implemented in a digital enzyme-linked immunosorbent assay (ELISA)
platform and able to detect attomolar concentrations of Tau protein, thereby unlocking the potential
of Tau as a serum-based AD biomarker [98]. So, over the last decade, yeast has developed from
a reliable model organism, merely used to gain more understanding of pathological Tau features
such as aggregation and phosphorylation, to a highly suitable platform model for disease-relevant
antigen production.
In the NFT of transgenic mice models, α-synuclein can co-localize with Tau and it has been shown
that α-synuclein can seed Tau aggregation in vitro and in vivo and even enhance Tau’s toxicity in
mice models [99–103]. It is, therefore, clear that the interplay between both proteins is important.
Yeast models have been developed that enable the study of both proteins and the resulting effects
on toxicity and aggregation [104,105]. Episomal expression of wt and A53T α-synuclein and wt and
P301L Tau resulted in increased phosphorylation on the AD2 epitope and Tau aggregation, but no
growth-inhibiting effect was detected [105]. The latter was in contrast to a previously reported
study [104], where synergistic toxicity was observed upon stable genomic integration of plasmids
expressing wt α-synuclein and wt Tau. This is in accordance with increased α-synuclein inclusion
formation and Tau phosphorylation/aggregation [105].
2.3. Future Perspectives
Baker’s yeast has been of interest to humans since the existence of brewing and bread-making.
Since these two activities have been subject to continuous improvement, research on S. cerevisiae’s
physiology was mainly application-driven. In contrast, focus on the fission yeast S. pombe was
mainly interested-driven and initial studies were performed to gain more insights in its mating type
system and sexual and cell division cycle [106]. Nevertheless, S. pombemight offer great potential as
a complementary model to study Tau biology since several features such as the cell division machinery,
cell polarity and cytoskeleton organization are more closely related to higher eukaryotes compared to
S. cerevisiae [106–108]. This organism could, therefore, be advantageous to study Tau characteristics
such as in vivo MT binding, which has not been observed so far in budding yeast models most likely
due to critical gene sequence differences. So far, binding to porcine MT has only been shown for yeast
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extracted Tau [88]. Indeed, fluorescence microscopy studies indicate potential binding of protein Tau
to MT in vivo in S. pombe cells. Moreover, preliminary data points out that several Tau epitopes also
become phosphorylated in S. pombe (data not shown). The precise role(s) of each of the fission yeast
Tau kinase orthologues remains unresolved.
Heinisch and colleague also proposed several arguments why the milk yeast K. lactis could serve
as a useful model to study Tau biology, more specifically the effects of energy signaling and oxidative
stress on Tau aggregation [109]. K. lactis has several advantages over the traditional baker’s yeast
model. For example, a respiratory metabolism more resembling that of mammalian cells. Moreover,
K. lactis did not undergo a whole genome duplication throughout evolution which limits the number
of redundant gene functions. This ensures a more easily trackable phenotype upon single gene
deletions [110].
Experimental methodologies used in the aforementioned reports, e.g., SinT assay or fluorescence
microscopy using a green fluorescent protein (GFP)-tagged Tau protein, are well suited for the study of
Tau aggregation, but lack applicability for analysis of Tau oligomerization. Since the current consensus
is that oligomeric, rather than aggregated, Tau is the toxic Tau species, neat technologies to study
oligomerization could enhance yeast’s value as a model for the study of neurodegenerative diseases
such as AD. An example is the use of a split-GFP sensor system. Several split-GFP technologies are
described in [111–115].
3. Humanized Yeast Models to Study Aβ Biology
3.1. Protein Aβ: Structure, Function and Aggregation
Glycoprotein amyloid precursor protein (APP) plays an important role in numerous biological
activities, ranging from neuronal development and homeostasis to signaling and intracellular
transport [116–119]. After synthesis in the endoplasmatic reticulum (ER), the protein is subsequently
transported from the Golgi apparatus to the plasma membrane where it is cleaved by α- and
γ-secretase or β- and γ-secretase following the non-amyloidogenic or amyloidogenic pathway,
respectively [120,121]. This cleavage yields several Aβ species with amino acid sequences varying from
40 to 51 amino acids with Aβ40 and Aβ42 being the final fragments [122,123]. While β-secretase activity
is primarily mediated by BACE1, γ-secretase activity actually requires the presence of 4 proteins;
Presenilin 1 or 2, Nicastrin, Presenilin enhancer 2 and Anterior pharynx defective 1 (Aph1) [124].
These peptides can then be released in the extracellular space where they can bind to a variety
of receptors or they remain associated with the plasma membrane and lipid raft structures [119].
The amyloidogenic pathway is central in the so-called “amyloid cascade hypothesis”, which states
that the formed Aβ structures sequentially oligomerize and aggregate thereby causing neurotoxicity
and dementia [125]. Aβ peptides can aggregate in different structural forms i.e., soluble oligomers,
protofibrils, but also insoluble amyloid fibrils and all of them feature β-sheet structures [126,127].
While the oligomers may spread throughout the brain, the fibrils can further assemble into plaques,
which are commonly found in the neocortex of the AD patient brains [128]. However, there is no
direct correlation between amyloid plaques and the loss of synapses and neurons in AD patient
brains [129–131].
In fact, cognitive deficits appear before plaque deposition or the deposition of insoluble amyloid
fibrils. Similarly to protein Tau, it is suggested that the Aβ oligomers trigger synapse dysfunction
and memory impairment [132,133]. Extracellular receptor-bound Aβ oligomers were proposed to
induce neurotoxic effects by causing mitochondrial dysfunction and oxidative stress in neuronal cells,
which can cause a massive calcium influx [134]. This can then impair the ability of cells to conduct
normal physiological functions [135].
It should be mentioned, however, that it is highly possible that different Aβ forms may contribute
to neurodegeneration at different disease stages [135]. A proposed link between Aβ and Tau pathology
is the Aβ aggregation-mediated kinase activation, which results in Tau hyperphosphorylation
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(see above) that in turn results in NFT formation. This is, however, only one possible hypothesis
linking these two proteins and their interplay is presumed to be more complex [135]. Other secondary,
toxicity inducing, effects of Aβ aggregation are the involvement of the innate immune system and
inflammatory responses [136–138].
To maintain Aβ protein homeostasis both in the brain and in plasma, production of Aβ is
counterbalanced by mechanisms such as proteolytic degradation [139–141], active transport via the
blood brain barrier [142–147] and deposition of Aβ in insoluble aggregates [148,149]. This does not only
involve neurons, but also other cells of the neurovascular unit, such as astrocytes [150–152]. Disruption
of any of these processes might result in neuropathology. Cathepsin B, for example, was identified as
a major Aβ-degrading enzyme and its expression level is altered in the brain of AD patients [153].
3.2. From Heterologously Expressed APP to Secretory Pathway-Targeted Aβ Peptides
Since Aβ peptides are generated by Secretase cleavage of APP, modelling of Aβ pathology in
yeast cells can be done via a number of approaches. The APP, or the Aβ peptides can be heterologously
expressed in yeast. Although there are no orthologues of the human Secretases in yeast present,
both α- and β-secretase activity has been reported [154,155], with the yeast proteases Yap3 and Mkc7
suggested to exhibit α-secretase activity [156,157]. γ-secretase activity was successfully reconstituted
in S. cerevisiae upon combined expression of APP-based substrates and human γ- secretase, resulting






















Figure 2. Humanized yeast model expressing human proteins, APP and γ-secretase: overview of
Secretase-mediated APP processing and Aβ peptide production. The scissors icon indicates cleavage
of the respective proteins.
As mentioned above, the γ-secretase complex consists of 4 different components and the influence
of different combinations of Presenilin and Aph1 proteins on function and substrate specificity of the
γ-secretase was tested in a yeast system [160,161]. Although differences were observed, the results
were not well in line with parallel studies performed in mammalian cells, which, they reasoned,
could be explained by the lack of additional proteins (e.g., GSAP and CD147) that affect γ-secretase
function and that are not present in yeast. Moreover, the same group found that Nicastrin can be
dispensable for protease activity of double-mutated γ-secretase, e.g., F411Y/S438P [162]. This first
group of yeast models, in which pre-Aβ components (i.e., APP-like substrates and Secretases) are
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expressed, offers the possibility to screen for components and drugs that interfere with Aβ peptide
generation and, therefore, have therapeutic potential.
The focus, however, has shifted more towards the expression of the actual Aβ peptides in yeast
cells. This has one major benefit since it limits the amount of heterologously expressed proteins in
yeast and, therefore, also any potential side reactions which result in non-Aβ pathology associated
phenotypes. In this context, the prion-forming capability of S. cerevisiae has also been exploited to gain
more insight in Aβ’s oligomerization and aggregation capability.
Sup35, for example, is a translation termination factor and has the natural propensity to form
self-propagating infectious amyloid aggregates which results in a prion phenotype “[PSI+]” [163].
Bagriantsev and colleague fused the MRF (middle- and release factor domain) of the protein
to Aβ42 and screened for the ability of an ade1-14 strain to grown on medium lacking adenine.
They showed that fusion of Aβ42 to this MRF domain resulted in a similar phenotype as did the N
(N-terminal domain) MRF protein, which makes up the entire amino acid sequence of the Sup35
protein. The N-terminal domain is required and sufficient for induction of the prion properties. Aβ42
induced oligomerization, resulting in the inability of Sup35 to terminate translation, enabled growth
of the ade1-14 strain on medium lacking adenine by restoring adenine prototrophy [164]. This setup
offers a neat in vivo system to screen for modulators of oligomerization. A second, independent study
yielded a similar result in that the Aβ42-Sup35 fusion was able to form aggregates, although less stable
compared to Sup35 aggregates, and restore the [PSI+] phenotype of Sup35 lacking the prion forming
domain [165].
To investigate Aβ42’s location and interactions, it was fused to GFP. Apart from inducing a growth
defect, Aβ42 also induced a heat shock response [166]. The latter is in correspondence with data
obtained from AD patients that indicate that heat shock protein expression is upregulated in AD as
a protective measure [167]. A study on oligomerization/aggregation modifiers using this Aβ42-GFP
construct suggested that folinic acid might assist in preventing Aβ42 misfolding and aggregation [168].
Recently, yeast was also used as a model to screen for rationally designed compounds [169].
More specifically, Thioflavin assays, circular dichroism measurements and transmission electron
microscopy were used to assess the efficiency of peptidomimetic inhibitors to inhibit Aβ42 aggregation
by targeting non-covalent interactions (Table 1). This way, two compounds were able to rescue
yeast from Aβ42-induced toxicity. Yeast also served as an excellent tool to shed more light on the
mechanism of action of the anti-histamine latrepirdine (Dimebon™) [170], which showed promising
aggregate clearing activity in vivo (Table 1). The compound was suggested to upregulate the
sequestering of aggregated GFP-Aβ42 into autophagic-like vesicles which get targeted for degradation.
Autophagy plays a crucial role in the removal of aggregated or misfolded proteins, such as Aβ,
in neurodegenerative diseases [171–173] and impaired clearance of autophagic vesicles is also observed
in the brains of AD mice models and patients [171–173]. Highly similar results were obtained in other
cell and animal models: Steele and colleagues reported that the treatment of cultured mammalian cells
with latrepirdine led to enhanced mTOR- and Atg5-dependent autophagy. Moreover, latrepirdine
treatment of TgCRND8 transgenic mice was associated with improved learning behavior and with
a reduction in accumulation of Aβ42 [174].
Finally, a yeast-based screen identified clioquinol and dihydropyrimidine-thiones as compounds
being able to ameliorate Aβ toxicity in a synergistic, metal-dependent, way via different mechanisms
such as increasing Aβ turnover, restoring vesicle trafficking and oxidative stress protection [175,176]
(Table 1). Again, also in transgenic mice models, treatment with clioquinol (analogue) compounds
inhibited Aβ accumulation [177] and resulted in a dramatic improvement in learning and memory,
accompanied by marked inhibition of AD-like neuropathology [178]. Finally, a study assessed the
clinical effect of clioquinol analogue PBT2 using human patient cohorts. Compared to the placebo
group, Aβ CSF concentration was reduced upon treating AD patients with PBT2. In addition,
some cognitive test results indicated an improvement in AD patients treated with the clioquinol
analogue [179]. These research and clinical studies highlight the fact that yeast-based compound
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screenings are extremely valuable to identify promising molecules that ameliorate Aβ pathology.
Secondly, in several cases, the proposed mechanism of action of a compound, based on insights
obtained from yeast research, was confirmed by other, often more comprehensive, pathological AD
models [174].
Aβ peptides are generated at the plasma membrane and can subsequently be secreted and
re-uptaken in the cell and eventually be found in the cytosol, mitochondria, secretory pathway and
autophagosomes [180]. To recapitulate Aβ’s multi-compartment trafficking, Treusch and colleagues
fused a Kar2 sequence to the N-terminus of Aβ42, targeting the peptide to the ER [181] (Figure 3).
After cleavage of this sequence, Aβ42 is released in the secretory pathway. The presence of a cell
wall prevents diffusing of the peptides in the medium, thereby allowing interaction with the plasma
membrane and endocytosis. Cell growth was decreased after expression of Aβ42 using a multicopy
plasmid and galactose-inducible promoter and this in contrast to Aβ40. Screening of an overexpression

















Figure 3. Humanized yeast model expressing GFP-fused Aβ peptides tagged with an endoplasmatic
reticulum (ER) or Golgi complex targeting sequence. Treusch and colleagues expressed Aβ42
N-terminally tagged with the Kar2 sequence, while D’Angelo and colleagues expressed Aβ42/ARC
N-terminally tagged with the α prepro-leader sequence (with and without a C-terminal GFP tag).
The scissors icon indicates cleavage of the respective proteins.
PICALM (phosphatidylinositol-binding Clathrin assembly protein), of which Yap1801 and
Yap1802 are the yeast homologues [182], was one of the toxicity suppressor hits and is one the
most highly validated AD risk factors. The exact role of PICALM in AD is unknown, but it is thought
to play a role in APP trafficking [183]. Since Aβ perturbs endocytotic trafficking, it was suggested that
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PICALM has a role in restoring this process. These findings were backed up by data obtained from rat
cortical neurons, in which Aβ-induced cell death was partly prevented upon PICALM expression [181].
A more recent study also reported on the beneficial role of PICALM, since it was able to reduce
Aβ42 oligomerization [183] (Table 1). In another article [184], the same yeast model was used to
study the effects of native Aβ and in addition to previously shown lower growth rate, a reduced
respiratory rate and elevated levels of reactive oxygen species (ROS) were exhibited. These are
hallmarks of mitochondrial and ubiquitin-proteasome system dysfunction, which also occur in neurons
and peripheral tissues of AD patients [185], and nicely illustrate the applicability of such a yeast model
to study the role of Aβ in cell stress and damage. In fact, these results were in accordance with findings
obtained from a yeast model after prolonged exposure to cytosolic Aβ42. Several signs of mitochondrial
dysfunction were observed, including increased ROS production, decreased mitochondrial membrane
potential and reduced oxygen consumption [184]. A major question that remains is how Aβ peptides
actually are taken up in the mitochondria.
In a follow-up study, using a more systems biology approach, the interplay between ER stress
and the unfolded protein response (UPR) were studied upon constitutive expression of Aβ40 and
Aβ42 [186]. In comparison to Aβ40 which only induced mild stress, Aβ42 expression resulted in
prolonged high stress and an UPR failing to cope with the unfolded protein load resulting in cellular
dysfunction, a shorter chronological lifespan and deregulation of lipid metabolism. These results are
highly relevant for other diseases as well, especially cancer and diabetes due to the emerging role of
the UPR in these diseases.
Using a similar strategy by fusing the mating type factor α prepro-leader sequence to Aβ, another
group also showed that targeting Aβ in the secretory pathway is essential for toxicity in yeast [182]
(Figure 3). The researchers tested both native and C-terminally GFP-tagged Aβ42 and AβARC and
detected aggregate formation and a more profound toxic effect in case of the prepro-Aβ-linker-GFP
constructs, especially AβARC for which they measured a decrease in respiratory rate. They also
suggested that Hsp104 could play a role in mediating this toxicity by favoring the conversion of
large aggregates into smaller oligomeric species. Western blot data showed a decreased protein level
in the case of native Aβ peptides, which indicated that the GFP moiety might have a stabilizing
effect. These results were not in line with the results published by Treusch and colleagues, since in
their research native Aβ42 expression resulted in significant toxicity when ending up in the secretory
pathway. Another difference was the presumed role of PICALM. In the paper published by D’Angelo
and colleagues, deletion of Yap1801 and Yap1802 resulted in a decrease in Aβ-induced toxicity.
Upon expression of PICALM, this toxic effect was partly restored. Therefore, more research is necessary
to shed light on the actual role of PICALM in Aβ-induced toxicity.
Since it is clear that AD, mitochondrial dysfunction and altered proteostasis are linked to
one another, two studies also more closely investigated the interplay between the Pitrilysin
Metallopeptidase 1 (PITRM1), an oligopeptide-digesting mitochondrial matrix enzyme, and Aβ.
In addition to its role in cleaving the mitochondrial targeting sequence (MTS) of proteins imported
across the inner mitochondrial membrane, it also disposes mitochondrial Aβ [187–190]. However,
in a first study, it was shown that the accumulation of Aβ peptides inhibits the activity of Cym1,
which is the yeast PITRM1 orthologue, leading to impaired MTS processing and accumulation of
precursor proteins [191]. In a second study, the effect of a missense mutation in this enzyme was
documented using yeast by modelling the R183Q mutation in the Cym1 protein [192]. This resulted
in a reduced Aβ42 degradation compared to wt Cym1, suggesting a pathogenic role of this mutated
protein, displaying similar behavior as in human beings.
Cenini and colleagues reported that Aβ peptides, especially Aβ42, inhibited mitochondrial protein
import by affecting an early process step when newly synthesized mitochondrial polypeptides are
exposed to the cytosolic environment, rather than affecting mitochondrial membrane potential, TOM
and TIM (Translocase of the outer and inner membrane, respectively) or respiratory chain metabolic
protein complex composition [193]. These findings are in contrast to the study described earlier in this
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paragraph [191], in which Aβ peptides indirectly interfered with the processing of imported precursor
proteins to the mature and active forms, which is a late step of the mitochondrial import reaction.
Finally, a C. glabrata model was used to assess toxicity of extracellular chemically-synthesized
Aβ [194] by determining the viable colony count, using a water-based assay. It was shown that Aβ
did bind the plasma membrane of C. glabrata, but the exact mechanism by which Aβ kills C. glabrata
remains to be determined. Interestingly, upon oligomerization Aβ loses its toxic effect, while Aβ has
a protective function against sodium hydroxide toxicity [195].
Table 1. Overview of Tau and Aβ toxicity modifiers identified using yeast-based screens.
Protein Toxicity Modifiers Description Other Models References
Tau Pin1 (yeast homologue Ess1)
Depletion of Pin1 isomerase activity results in
reduced growth of Tau expressing yeast cells.
mouse model [93,196,197]
Aβ peptidomimetic inhibitors Inhibition of Aβ42 aggregation by peptidomimetics. - [169]
Aβ latrepirdine (Dimebon™)
Latrepirdine induces autophagy and decreases the





Small molecule screen identified several






Phenotypic small molecule yeast screen identified
dihydropyrimidine-thiones that rescue Aβ-induced





Screening of overexpression library yielded
suppressors and enhancers of Aβ42 toxicity,
including the PICALM suppressor.
rat cortical neurons [181–183]
4. Humanized Yeast Models to Study Frameshift Ubiquitin Mutant UBB+1 Biology
Yeast models expressing the frameshift Ubiquitin mutant UBB+1 have also been developed.
UBB+1 accumulation is found in neurons of all AD patients, but absent in those of Parkinson’s
disease patients, and co-localizes with the MC1 marker, i.e., NFT [198]. How UBB+1 is related
to aberrant and phosphorylated Tau protein, both spatially and temporally, still needs to be
elucidated [198]. The authors suggested that these mutant proteins may be responsible for the lack of
multi-ubiquitination of the hyperphosphorylated Tau fraction found in the NFT [199]. These UBB+1
molecules are unable to bind to lysine residues in target molecules, since they lack the COOH-terminal
glycine residue in the first repeat region, which is essential for subsequent multi-ubiquitination and
activation of the proteasomal machinery [200]. Upon expression of UBB+1 in yeast, the protein becomes
a substrate of the UPR and accumulated UBB+1 impairs the UPR both in yeast and mammalian
cells [201–204]. This results in an accumulation of polyubiquitinated substrates which do not get
degraded, partially accomplished by the inhibition of deubiquitinating enzymes [205].
Despite this impairment, no toxicity is observed. By contrast, upon prolonged expression of high
levels of UBB+1, cell death and mitochondrial dysfunction were observed in neuronal cells and yeast
models [203,206,207]. Interestingly to keep in mind here is the fact that UBB+1 can be a toxic protein by
itself, but it could also act as a potent modifier of toxicity of other neurotoxic proteins, such as Tau
and Aβ. Therefore, yeast models combining expression of these proteins in combination with UBB+1
could unravel molecular mechanisms important in AD, such as UPS dysfunction and mitochondrial
activity [208].
5. Studying Prion Characteristics of Aβ and Tau in Yeast
Prions are self-propagating infection protein species. They were first discovered as causative
agents in mammalian diseases like Creutzfeldt-Jakob or Scrapie [209,210]. There, a normal protein
(PrPC) conformationally changes into amalicious and infectious PrPSc prion protein [211]. Besides these
disease-causing prions, a plethora of prions with mostly unknown function has been discovered also
in yeast [212,213]. Except for Podospora anserina’s [Het-s] prion, most functions of all these prions are
unclear and all are toxic, or at least growth-inhibitory, but still are supposed to be beneficial for the
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survival of cells under stress conditions [214–216]. To ensure optimal survival but limit malicious
effects, prion formation has to be tightly controlled and carefully balanced. Several factors promote or
inhibit prion formation like Hsp104, Hsp70, Sse1, Cur1, Btn2 [217–221]. Interestingly, some of these
factors, like Hsp104, promote and inhibit prion formation depending on co-factors and expression
levels [222,223].
Many human diseases are described or at least suspected to be prion diseases such as type 2
diabetes mellitus, AD or Huntington’s disease [209,224,225]. Most prions are amyloid and, as its name
indicates, Aβ for example stacks β-sheets to form toxic amyloid oligomers which were shown to be
transmittable and infectious in mice [226–228]. If Aβ is a prion or not is still to be discussed but more
and more hints are pointing towards it [227,229]. It is almost accepted that the second key-player
in AD, Tau, might be a prion as well. Several studies point towards the MT binding domain of Tau
being responsible for aggregation and prionization [230,231]. Several of the yeast models to study AD
discussed above [181,182,191,232] are not only used to study the impact of Aβ or Tau on biochemical
pathways and on organelles, but also the prion characteristics of these proteins are the focus of research.
Evidence for Aβ and Tau being prions were found in mice or other higher eukaryotic model organisms
but not in yeast. Tau is hyperphosphorylated and forms aggregates but it is hardly toxic in yeast
models [95]. Also, transmission of neither aggregated Tau nor Aβ from affected yeast to healthy
strains has been shown so far. But still, there are excellent and robust yeast in vivo techniques to
study prion domains and push this field towards greater success. Brachmann and colleagues extended
a model developed by Schlumperger and colleagues which makes use of the Ure2 prion system in
yeast [233,234]. By replacing promoters of reporter genes by the Ure2 suppressed DAL5 promotor
(pDAL5) it is possible to track Ure2-prion strength. If Ure2 is in a non-prion state it binds Gln3,
the transcription factor activating pDAL5. When Ure2 forms its prion, [URE3], it releases Gln3 and,
thus, induces the reporter gene expression through pDAL5. By replacing Ure2’s own prion domain by
any protein domain, one can easily test if it is a prion domain. By making use of different reporter
genes it is not only possible to check for a domain to be a prion domain in a black-white manner,
like with the URA reporter, but it is also possible to measure the strength of a prion domain by using
ADE2 as a reporter. The “redness” of the reporter strain indicates the strength of prion formation and
thus the release of Gln3 from unprionized Ure2.
Another technique based on a similar principle is the recently developed yTRAP [235]. Here,
suspected prions are fused to a synthetic transcription factor, the synTA. When the protein is soluble
and thus not prionized, it allows the synTA to bind the promotor and induce expression of a fluorescent
protein, in this case mNeonGreen or mKate2. When aggregated, the transcription factor cannot reach
its promotor and the expression of the reporter gene is suppressed. An overview of several traditional
and more innovative yeast techniques that play(ed) a crucial role in unravelling Tau and Aβ functions
such as protein–protein interaction and prion formation can be found in Table 2.
Table 2. Summary of yeast-based techniques applicable in studies on proteins involved in
neurodegenerative diseases.
Technique Used for Description
Split-GFP system [111–115,236] Protein–protein interaction
GFP fluorescence is reconstituted when its two subunits are
in close proximity.
Synthetic genetic array [237] Synthetic lethality
Approach for the systematic construction of double mutants
for large-scale mapping of synthetic genetic interactions.
Yeast two-hybrid [238] Protein–protein interaction Protein interaction leads to reporter gene expression.
Prion-forming assay [233] Prion forming
The prion domain of the yeast Ure2 prion is replaced by
a potential prion domain of any protein. Reporter gene
expression is induced if this domain can complement for the
Ure2 prion domain.
Yeast transcriptional reporting
aggregating proteins (yTRAP) [235]
Prion forming
High-throughput quantitative prion forming assay. Uses
fluorescence as quantifiable reporter.
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6. Conclusions
It is clear from the above discussed articles that yeast has proven its value in modern AD
research. Although S. cerevisiae models are most prevalent, it is inspiring to see that alternative
models such as S. pombe or C. glabrata are gaining popularity. The pathobiology of proteins such
as Tau and Aβ is robustly recapitulated in yeast. Research using these models has shed more
light on the oligomerization/aggregation and prion properties of these proteins, including their
role in mitochondrial dysfunction and altered proteostasis, which are two important pathological
AD-related cellular processes. This, in combination with the intrinsic benefits of using yeast such
as speed and lower costs of research, puts these humanized yeast models in a unique position as
a complementary model organism. Therefore, yeast may play a crucial role in overcoming the major
future challenges in AD research, including identifying the relationship between all these different
pathological AD-related processes.
Author Contributions: D.S. wrote the majority of this manuscript. Other listed authors provided figures/tables,
wrote specific sections and/or reviewed the content.
Funding: David Seynnaeve is supported by an Aspirant fellowship (1101317N) of Research Foundation-Flanders
(FWO) and Vanessa Franssens by a post-doctoral fellowship (1287517N) of FWO. Joke Verelst is supported by
an FWO SBO Fellowship (1S80418N). Mara Del Vecchio, Gernot Fruhmann and Melody Cools are financed
through FWO SBO (S006617N) and KU Leuven funding granted to Joris Winderickx. Work in Daniel P. Mulvihill’s
lab is supported by the University of Kent and by funding from the Biotechnology and Biological Sciences
Research Council
Acknowledgments: Human head and scissors icon made by Freepik from www.flaticon.com.
Conflicts of Interest: The authors declare no conflicts of interest.
References
1. Prince, M.; Guerchet, M.; Prina, M. The Epidemiology and Impact of Dementia: Current State and Future
Trends. Available online: http://www.who.int/mental_health/neurology/en/ (accessed on 26 March 2015).
2. Prince, M.; Bryce, R.; Albanese, E.; Wimo, A.; Ribeiro, W.; Ferri, C.P. The global prevalence of dementia:
A systematic review and metaanalysis. Alzheimer’s Dement. 2013, 9, 63–75. [CrossRef] [PubMed]
3. Abbott, A. Dementia: A problem for our age. Nature 2011, 475, S2–S4. [CrossRef] [PubMed]
4. Norfray, J.F.; Provenzale, J.M. Alzheimer’s Disease: Neuropathologic Findings and Recent Advances in
Imaging. Am. J. Roentgenol. 2004, 182, 3–13. [CrossRef] [PubMed]
5. Marsh, J.; Alifragis, P. Synaptic dysfunction in Alzheimer’s disease: The effects of amyloid beta on synaptic
vesicle dynamics as a novel target for therapeutic intervention. Neural Regen. Res. 2018, 13, 616–623.
[CrossRef] [PubMed]
6. Selkoe, D.J. Alzheimer’s Disease Is a Synaptic Failure. Science 2002, 298, 789–791. [CrossRef] [PubMed]
7. Backman, L.; Jones, S.; Berger, A.-K.; Laukka, E.J.; Small, B.J. Multiple cognitive deficits during the transition
to Alzheimer’s disease. J. Intern. Med. 2004, 256, 195–204. [CrossRef] [PubMed]
8. Lang, A.E. Clinical trials of disease-modifying therapies for neurodegenerative diseases: The challenges and
the future. Nat. Med. 2010, 16, 1223–1226. [CrossRef] [PubMed]
9. Irie, K.; Murakami, K.; Masuda, Y.; Morimoto, A.; Ohigashi, H.; Ohashi, R.; Takegoshi, K.; Nagao, M.;
Shimizu, T.; Shirasawa, T. Structure of β-amyloid fibrils and its relevance to their neurotoxicity: Implications
for the pathogenesis of Alzheimer’s disease. J. Biosci. Bioeng. 2005, 99, 437–447. [CrossRef] [PubMed]
10. Ittner, L.M.; Götz, J. Amyloid-β and tau—A toxic pas de deux in Alzheimer’s disease. Nat. Rev. Neurosci.
2011, 12, 67–72. [CrossRef] [PubMed]
11. Goffeau, A.; Barrell, B.G.; Bussey, H.; Davis, R.W.; Dujon, B.; Feldmann, H.; Galibert, F.; Hoheisel, J.D.;
Jacq, C.; Johnston, M.; et al. Life with 6000 genes. Science 1996, 274, 563–567. [CrossRef]
12. Botstein, D.; Chervitz, S.A.; Cherry, J.M. Yeast as a model organism. Science 1997, 277, 1259–1260. [CrossRef]
[PubMed]
13. Petranovic, D.; Tyo, K.; Vemuri, G.N.; Nielsen, J. Prospects of yeast systems biology for human health:
Integrating lipid, protein and energy metabolism. FEMS Yeast Res. 2010, 10, 1046–1059. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 1947 15 of 26
14. Winderickx, J.; Delay, C.; De Vos, A.; Klinger, H.; Pellens, K.; Vanhelmont, T.; Van Leuven, F.; Zabrocki, P.
Protein folding diseases and neurodegeneration: Lessons learned from yeast. Biochim. Biophys. Acta Mol.
Cell Res. 2008, 1783, 1381–1395. [CrossRef] [PubMed]
15. Tenreiro, S.; Munder, M.C.; Alberti, S.; Outeiro, T.F. Harnessing the power of yeast to unravel the molecular
basis of neurodegeneration. J. Neurochem. 2013, 127, 438–452. [CrossRef] [PubMed]
16. Mohammadi, S.; Saberidokht, B.; Subramaniam, S.; Grama, A. Scope and limitations of yeast as a model
organism for studying human tissue-specific pathways. BMC Syst. Biol. 2015, 9, 96. [CrossRef] [PubMed]
17. Migheli, A.; Butler, M.; Brown, K.; Shelanski, M. Light and electron microscope localization of the
microtubule-associated tau protein in rat brain. J. Neurosci. 1988, 8, 1846–1851. [CrossRef] [PubMed]
18. Papasozomenos, S.C.; Binder, L.I. Phosphorylation determines two distinct species of tau in the central
nervous system. Cell Motil. Cytoskelet. 1987, 8, 210–226. [CrossRef] [PubMed]
19. Binder, L.I.; Frankfurter, A.; Rebhun, L.I. The distribution of tau in the mammalian central nervous system.
J. Cell Biol. 1985, 101, 1371–1378. [CrossRef] [PubMed]
20. Wilhelmsen, K.C.; Lynch, T.; Pavlou, E.; Higgins, M.; Nygaard, T.G. Localization of
disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22. Am. J. Hum. Genet. 1994,
55, 1159–1165. [PubMed]
21. Pooler, A.M.; Phillips, E.C.; Lau, D.H.W.; Noble, W.; Hanger, D.P. Physiological release of endogenous tau is
stimulated by neuronal activity. EMBO Rep. 2013, 14, 389–394. [CrossRef] [PubMed]
22. Yamada, K. Extracellular Tau and Its Potential Role in the Propagation of Tau Pathology. Front. Neurosci.
2017, 11. [CrossRef] [PubMed]
23. Ittner, L.M.; Ke, Y.D.; Delerue, F.; Bi, M.; Gladbach, A.; van Eersel, J.; Wölfing, H.; Chieng, B.C.; Christie, M.J.;
Napier, I.A.; et al. Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer’s Disease Mouse
Models. Cell 2010, 142, 387–397. [CrossRef] [PubMed]
24. Drechsel, D.N.; Hyman, A.A.; Cobb, M.H.; Kirschner, M.W. Modulation of the dynamic instability of tubulin
assembly by the microtubule-associated protein tau. Mol. Biol. Cell 1992, 3, 1141–1154. [CrossRef] [PubMed]
25. Crowther, R.A. Straight and paired helical filaments in Alzheimer disease have a common structural unit.
Proc. Natl. Acad. Sci. USA 1991, 88, 2288–2292. [CrossRef] [PubMed]
26. Wischik, C.M.; Crowther, R.A.; Stewart, M.; Roth, M. Subunit structure of paired helical filaments in
Alzheimer’s disease. J. Cell Biol. 1985, 100, 1905–1912. [CrossRef] [PubMed]
27. Ichihara, K.; Kitazawa, H.; Iguchi, Y.; Hotani, H.; Itoh, T.J. Visualization of the stop of microtubule
depolymerization that occurs at the high-density region of microtubule-associated protein 2 (MAP2).
J. Mol. Biol. 2001, 312, 107–118. [CrossRef] [PubMed]
28. Violet, M.; Delattre, L.; Tardivel, M.; Sultan, A.; Chauderlier, A.; Caillierez, R.; Talahari, S.; Nesslany, F.;
Lefebvre, B.; Bonnefoy, E.; et al. A major role for Tau in neuronal DNA and RNA protection in vivo under
physiological and hyperthermic conditions. Front. Cell. Neurosci. 2014, 8. [CrossRef] [PubMed]
29. Frandemiche, M.L.; De Seranno, S.; Rush, T.; Borel, E.; Elie, A.; Arnal, I.; Lante, F.; Buisson, A.
Activity-Dependent Tau Protein Translocation to Excitatory Synapse Is Disrupted by Exposure to
Amyloid-Beta Oligomers. J. Neurosci. 2014, 34, 6084–6097. [CrossRef] [PubMed]
30. Stamer, K.; Vogel, R.; Thies, E.; Mandelkow, E.; Mandelkow, E.-M. Tau blocks traffic of organelles,
neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J. Cell Biol. 2002, 156, 1051–1063.
[CrossRef] [PubMed]
31. Dixit, R.; Ross, J.L.; Goldman, Y.E.; Holzbaur, E.L.F. Differential Regulation of Dynein and Kinesin Motor
Proteins by Tau. Science 2008, 319, 1086–1089. [CrossRef] [PubMed]
32. Konzack, S.; Thies, E.; Marx, A.; Mandelkow, E.-M.; Mandelkow, E. Swimming against the Tide: Mobility of
the Microtubule-Associated Protein Tau in Neurons. J. Neurosci. 2007, 27, 9916–9927. [CrossRef] [PubMed]
33. Vershinin, M.; Carter, B.C.; Razafsky, D.S.; King, S.J.; Gross, S.P. Multiple-motor based transport and its
regulation by Tau. Proc. Natl. Acad. Sci. USA 2007, 104, 87–92. [CrossRef] [PubMed]
34. Utton, M.A.; Noble, W.J.; Hill, J.E.; Anderton, B.H.; Hanger, D.P. Molecular motors implicated in the axonal
transport of tau and alpha-synuclein. J. Cell Sci. 2005, 118, 4645–4654. [CrossRef] [PubMed]
35. Kanaan, N.M.; Morfini, G.A.; LaPointe, N.E.; Pigino, G.F.; Patterson, K.R.; Song, Y.; Andreadis, A.; Fu, Y.;
Brady, S.T.; Binder, L.I. Pathogenic Forms of Tau Inhibit Kinesin-Dependent Axonal Transport through
a Mechanism Involving Activation of Axonal Phosphotransferases. J. Neurosci. 2011, 31, 9858–9868.
[CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 1947 16 of 26
36. Magnani, E.; Fan, J.; Gasparini, L.; Golding, M.; Williams, M.; Schiavo, G.; Goedert, M.; Amos, L.A.;
Spillantini, M.G. Interaction of tau protein with the dynactin complex. EMBO J. 2007, 26, 4546–4554.
[CrossRef] [PubMed]
37. Caceres, A.; Kosik, K.S. Inhibition of neurite polarity by tau antisense oligonucleotides in primary cerebellar
neurons. Nature 1990, 343, 461–463. [CrossRef] [PubMed]
38. Wang, Y.; Mandelkow, E. Tau in physiology and pathology. Nat. Rev. Neurosci. 2016, 17, 22–35. [CrossRef]
[PubMed]
39. Goedert, M.; Spillantini, M.G.; Potier, M.C.; Ulrich, J.; Crowther, R.A. Cloning and sequencing of the cDNA
encoding an isoform of microtubule-associated protein tau containing four tandem repeats: Differential
expression of tau protein mRNAs in human brain. EMBO J. 1989, 8, 393–399. [PubMed]
40. Himmler, A.; Drechsel, D.; Kirschner, M.W.; Martin, D.W. Tau consists of a set of proteins with repeated
C-terminal microtubule-binding domains and variable N-terminal domains. Mol. Cell. Biol. 1989, 9,
1381–1388. [CrossRef] [PubMed]
41. Rosenberg, K.J.; Ross, J.L.; Feinstein, H.E.; Feinstein, S.C.; Israelachvili, J. Complementary dimerization of
microtubule-associated tau protein: Implications for microtubule bundling and tau-mediated pathogenesis.
Proc. Natl. Acad. Sci. USA 2008, 105, 7445–7450. [CrossRef] [PubMed]
42. Bunker, J.M.; Wilson, L.; Jordan, M.A.; Feinstein, S.C. Modulation of microtubule dynamics by tau in living
cells: Implications for development and neurodegeneration. Mol. Biol. Cell 2004, 15, 2720–2728. [CrossRef]
[PubMed]
43. Lu, M.; Kosik, K.S. Competition for microtubule-binding with dual expression of tau missense and splice
isoforms. Mol. Biol. Cell 2001, 12, 171–184. [CrossRef] [PubMed]
44. Derisbourg, M.; Leghay, C.; Chiappetta, G.; Fernandez-Gomez, F.-J.; Laurent, C.; Demeyer, D.; Carrier, S.;
Buée-Scherrer, V.; Blum, D.; Vinh, J.; et al. Role of the Tau N-terminal region in microtubule stabilization
revealed by new endogenous truncated forms. Sci. Rep. 2015, 5, 9659. [CrossRef] [PubMed]
45. Chen, J.; Kanai, Y.; Cowan, N.J.; Hirokawa, N. Projection domains of MAP2 and tau determine spacings
between microtubules in dendrites and axons. Nature 1992, 360, 674–677. [CrossRef] [PubMed]
46. Sattilaro, R.F.; Dentler, W.L.; LeCluyse, E.L. Microtubule-associated proteins (MAPs) and the organization of
actin filaments in vitro. J. Cell Biol. 1981, 90, 467–473. [CrossRef] [PubMed]
47. Correas, I.; Padilla, R.; Avila, J. The tubulin-binding sequence of brain microtubule-associated proteins, tau
and MAP-2, is also involved in actin binding. Biochem. J. 1990, 269, 61–64. [CrossRef] [PubMed]
48. Rendon, A.; Jung, D.; Jancsik, V. Interaction of microtubules and microtubule-associated proteins (MAPs)
with rat brain mitochondria. Biochem. J. 1990, 269, 555–556. [CrossRef] [PubMed]
49. Brandt, R.; Léger, J.; Lee, G. Interaction of tau with the neural plasma membrane mediated by tau’s
amino-terminal projection domain. J. Cell Biol. 1995, 131, 1327–1340. [CrossRef] [PubMed]
50. Zmuda, J.F.; Rivas, R.J. Actin disruption alters the localization of tau in the growth cones of cerebellar granule
neurons. J. Cell Sci. 2000, 113, 2797–2809. [PubMed]
51. Manczak, M.; Reddy, P.H. Abnormal interaction between the mitochondrial fission protein Drp1 and
hyperphosphorylated tau in Alzheimer’s disease neurons: Implications for mitochondrial dysfunction and
neuronal damage. Hum. Mol. Genet. 2012, 21, 2538–2547. [CrossRef] [PubMed]
52. Bhaskar, K.; Hobbs, G.A.; Yen, S.-H.; Lee, G. Tyrosine phosphorylation of tau accompanies disease
progression in transgenic mouse models of tauopathy. Neuropathol. Appl. Neurobiol. 2010, 36, 462–477.
[CrossRef] [PubMed]
53. Lee, G.; Newman, S.T.; Gard, D.L.; Band, H.; Panchamoorthy, G. Tau interacts with src-family non-receptor
tyrosine kinases. J. Cell Sci. 1998, 111, 3167–3177. [PubMed]
54. Lee, G.; Thangavel, R.; Sharma, V.M.; Litersky, J.M.; Bhaskar, K.; Fang, S.M.; Do, L.H.; Andreadis, A.;
Van Hoesen, G.; Ksiezak-Reding, H. Phosphorylation of Tau by Fyn: Implications for Alzheimer’s Disease.
J. Neurosci. 2004, 24, 2304–2312. [CrossRef] [PubMed]
55. Dujardin, S.; Bégard, S.; Caillierez, R.; Lachaud, C.; Delattre, L.; Carrier, S.; Loyens, A.; Galas, M.-C.;
Bousset, L.; Melki, R.; et al. Ectosomes: A New Mechanism for Non-Exosomal Secretion of Tau Protein.
PLoS ONE 2014, 9, e100760. [CrossRef] [PubMed]
56. Calafate, S.; Buist, A.; Miskiewicz, K.; Vijayan, V.; Daneels, G.; de Strooper, B.; de Wit, J.; Verstreken, P.;
Moechars, D. Synaptic Contacts Enhance Cell-to-Cell Tau Pathology Propagation. Cell Rep. 2015, 11,
1176–1183. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 1947 17 of 26
57. Tardivel, M.; Bégard, S.; Bousset, L.; Dujardin, S.; Coens, A.; Melki, R.; Buée, L.; Colin, M. Tunneling nanotube
(TNT)-mediated neuron-to neuron transfer of pathological Tau protein assemblies. Acta Neuropathol. Commun.
2016, 4, 117. [CrossRef] [PubMed]
58. Wang, Y.; Balaji, V.; Kaniyappan, S.; Krüger, L.; Irsen, S.; Tepper, K.; Chandupatla, R.; Maetzler, W.;
Schneider, A.; Mandelkow, E.; Mandelkow, E.-M. The release and trans-synaptic transmission of Tau via
exosomes. Mol. Neurodegener. 2017, 12, 5. [CrossRef] [PubMed]
59. Guo, J.L.; Lee, V.M.Y. Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases.
Nat. Med. 2014, 20, 130–138. [CrossRef] [PubMed]
60. Goode, B.L.; Denis, P.E.; Panda, D.; Radeke, M.J.; Miller, H.P.; Wilson, L.; Feinstein, S.C. Functional
interactions between the proline-rich and repeat regions of tau enhance microtubule binding and assembly.
Mol. Biol. Cell 1997, 8, 353–365. [CrossRef] [PubMed]
61. Sillen, A.; Barbier, P.; Landrieu, I.; Lefebvre, S.; Wieruszeski, J.-M.; Leroy, A.; Peyrot, V.; Lippens, G. NMR
Investigation of the Interaction between the Neuronal Protein Tau and the Microtubules. Biochemistry 2007.
[CrossRef] [PubMed]
62. Hanger, D.P.; Seereeram, A.; Noble, W. Mediators of tau phosphorylation in the pathogenesis of Alzheimer’s
disease. Expert Rev. Ther. 2009, 9, 1647–1666. [CrossRef] [PubMed]
63. Sergeant, N.; Bretteville, A.; Hamdane, M.; Caillet-Boudin, M.-L.; Grognet, P.; Bombois, S.; Blum, D.;
Delacourte, A.; Pasquier, F.; Vanmechelen, E.; et al. Biochemistry of Tau in Alzheimer’s disease and related
neurological disorders. Expert Rev. Proteom. 2008, 5, 207–224. [CrossRef] [PubMed]
64. Domise, M.; Didier, S.; Marinangeli, C.; Zhao, H.; Chandakkar, P.; Buée, L.; Viollet, B.; Davies, P.;
Marambaud, P.; Vingtdeux, V. AMP-activated protein kinase modulates tau phosphorylation and tau
pathology in vivo. Sci. Rep. 2016, 6, 26758. [CrossRef] [PubMed]
65. Cavallini, A.; Brewerton, S.; Bell, A.; Sargent, S.; Glover, S.; Hardy, C.; Moore, R.; Calley, J.; Ramachandran, D.;
Poidinger, M.; et al. An unbiased approach to identifying tau kinases that phosphorylate tau at sites
associated with alzheimer disease. J. Biol. Chem. 2013, 288, 23331–23347. [CrossRef] [PubMed]
66. Trinczek, B.; Biernat, J.; Baumann, K.; Mandelkow, E.M.; Mandelkow, E. Domains of tau protein, differential
phosphorylation, and dynamic instability of microtubules. Mol. Biol. Cell 1995, 6, 1887–1902. [CrossRef]
[PubMed]
67. Hanger, D.P.; Anderton, B.H.; Noble, W. Tau phosphorylation: The therapeutic challenge for
neurodegenerative disease. Trends Mol. Med. 2009, 15, 112–119. [CrossRef] [PubMed]
68. Lu, P.-J.; Wulf, G.; Zhou, X.Z.; Davies, P.; Lu, K.P. The prolyl isomerase Pin1 restores the function of
Alzheimer-associated phosphorylated tau protein. Nature 1999, 399, 784–788. [CrossRef] [PubMed]
69. von Bergen, M.; Friedhoff, P.; Biernat, J.; Heberle, J.; Mandelkow, E.M.; Mandelkow, E. Assembly of tau
protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311))
forming beta structure. Proc. Natl. Acad. Sci. USA 2000, 97, 5129–5134. [CrossRef] [PubMed]
70. Dickey, C.A.; Kamal, A.; Lundgren, K.; Klosak, N.; Bailey, R.M.; Dunmore, J.; Ash, P.; Shoraka, S.;
Zlatkovic, J.; Eckman, C.B.; et al. The high-affinity HSP90-CHIP complex recognizes and selectively degrades
phosphorylated tau client proteins. J. Clin. Investig. 2007, 117, 648–658. [CrossRef] [PubMed]
71. Šimic´, G.; Babic´ Leko, M.; Wray, S.; Harrington, C.; Delalle, I.; Jovanov-Miloševic´, N.; Bažadona, D.; Buée, L.;
de Silva, R.; Giovanni, G.D.; et al. Tau protein hyperphosphorylation and aggregation in alzheimer’s
disease and other tauopathies, and possible neuroprotective strategies. Biomolecules 2016, 6, 2–28. [CrossRef]
[PubMed]
72. Berger, Z.; Roder, H.; Hanna, A.; Carlson, A.; Rangachari, V.; Yue, M.; Wszolek, Z.; Ashe, K.; Knight, J.;
Dickson, D.; et al. Accumulation of Pathological Tau Species and Memory Loss in a Conditional Model of
Tauopathy. J. Neurosci. 2007, 27, 3650–3662. [CrossRef] [PubMed]
73. Bretteville, A.; Planel, E. Tau aggregates: Toxic, inert, or protective species? J. Alzheimer’s Dis. 2008, 14,
431–436. [CrossRef]
74. Cowan, C.M.; Mudher, A. Are tau aggregates toxic or protective in tauopathies? Front. Neurol. 2013, 4, 1–13.
[CrossRef] [PubMed]
75. Maeda, S.; Sahara, N.; Saito, Y.; Murayama, M.; Yoshiike, Y.; Kim, H.; Miyasaka, T.; Murayama, S.; Ikai, A.;
Takashima, A. Granular Tau Oligomers as Intermediates of Tau Filaments. Biochemistry 2007, 46, 3856–3861.
[CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 1947 18 of 26
76. Lasagna-Reeves, C.A.; Castillo-Carranza, D.L.; Sengupta, U.; Sarmiento, J.; Troncoso, J.; Jackson, G.R.;
Kayed, R. Identification of oligomers at early stages of tau aggregation in Alzheimer’s disease. FASEB J.
2012, 26, 1946–1959. [CrossRef] [PubMed]
77. Hutton, M.; Lendon, C.L.; Rizzu, P.; Baker, M.; Froelich, S.; Houlden, H.; Pickering-Brown, S.; Chakraverty, S.;
Isaacs, A.; Grover, A.; et al. Association of missense and 5′-splice-site mutations in tau with the inherited
dementia FTDP-17. Nature 1998, 393, 702–705. [CrossRef] [PubMed]
78. Poorkaj, P.; Bird, T.D.; Wijsman, E.; Nemens, E.; Garruto, R.M.; Anderson, L.; Andreadis, A.; Wiederholt, W.C.;
Raskind, M.; Schellenberg, G.D. Tau is a candidate gene for chromosome 17 frontotemporal dementia.
Ann. Neurol. 1998, 43, 815–825. [CrossRef] [PubMed]
79. Spillantini, M.G.; Murrell, J.R.; Goedert, M.; Farlow, M.R.; Klug, A.; Ghetti, B. Mutation in the tau gene in
familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. USA 1998, 95, 7737–7741.
[CrossRef] [PubMed]
80. Spillantini, M.G.; Bird, T.D.; Ghetti, B. Frontotemporal dementia and Parkinsonism linked to chromosome
17: A new group of tauopathies. Brain Pathol. 1998, 8, 387–402. [CrossRef] [PubMed]
81. Rademakers, R.; Cruts, M.; van Broeckhoven, C. The role of tau (MAPT) in frontotemporal dementia and
related tauopathies. Hum. Mutat. 2004, 24, 277–295. [CrossRef] [PubMed]
82. Dermaut, B.; Kumar-Singh, S.; Rademakers, R.; Theuns, J.; Cruts, M.; Van Broeckhoven, C. Tau is central
in the genetic Alzheimer–frontotemporal dementia spectrum. Trends Genet. 2005, 21, 664–672. [CrossRef]
[PubMed]
83. D’Souza, I.; Poorkaj, P.; Hong, M.; Nochlin, D.; Lee, V.M.; Bird, T.D.; Schellenberg, G.D. Missense and silent
tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting
multiple alternative RNA splicing regulatory elements. Proc. Natl. Acad. Sci. USA 1999, 96, 5598–5603.
[CrossRef] [PubMed]
84. Barghorn, S.; Zheng-Fischhöfer, Q.; Ackmann, M.; Biernat, J.; von Bergen, M.; Mandelkow, E.M.;
Mandelkow, E. Structure, microtubule interactions, and paired helical filament aggregation by tau mutants
of frontotemporal dementias. Biochemistry 2000, 39, 11714–11721. [CrossRef] [PubMed]
85. Hong, M.; Zhukareva, V.; Vogelsberg-Ragaglia, V.; Wszolek, Z.; Reed, L.; Miller, B.I.; Geschwind, D.H.;
Bird, T.D.; McKeel, D.; Goate, A.; et al. Mutation-specific functional impairments in distinct tau isoforms of
hereditary FTDP-17. Science 1998, 282, 1914–1917. [CrossRef] [PubMed]
86. Roberson, E.D.; Scearce-Levie, K.; Palop, J.J.; Yan, F.; Cheng, I.H.; Wu, T.; Gerstein, H.; Yu, G.-Q.; Mucke, L.
Reducing Endogenous Tau Ameliorates Amyloid β-Induced Deficits in an Alzheimer’s Disease Mouse
Model. Science 2007, 316, 750–754. [CrossRef] [PubMed]
87. Vandebroek, T.; Vanhelmont, T.; Terwel, D.; Borghgraef, P.; Lemaire, K.; Snauwaert, J.; Wera, S.; Van Leuven, F.;
Winderickx, J. Identification and isolation of a hyperphosphorylated, conformationally changed intermediate
of human protein tau expressed in yeast. Biochemistry 2005, 44, 11466–11475. [CrossRef] [PubMed]
88. Vanhelmont, T.; Vandebroek, T.; De Vos, A.; Terwel, D.; Lemaire, K.; Anandhakumar, J.; Franssens, V.;
Swinnen, E.; Van Leuven, F.; Winderickx, J. Serine-409 phosphorylation and oxidative damage define
aggregation of human protein tau in yeast. FEMS Yeast Res. 2010, 10, 992–1005. [CrossRef] [PubMed]
89. Vandebroek, T.; Terwel, D.; Vanhelmont, T.; Gysemans, M.; Van Haesendonck, C.; Engelborghs, Y.;
Winderickx, J.; Van Leuven, F. Microtubule binding and clustering of human Tau-4R and Tau-P301L proteins
isolated from yeast deficient in orthologues of glycogen synthase kinase-3beta or cdk5. J. Biol. Chem. 2006,
281, 25388–25397. [CrossRef] [PubMed]
90. De Vos, A.; Anandhakumar, J.; Van den Brande, J.; Verduyckt, M.; Franssens, V.; Winderickx, J.; Swinnen, E.
Yeast as a model system to study tau biology. Int. J. Alzheimers Dis. 2011, 2011, 428970. [CrossRef] [PubMed]
91. Zambrano, C.A.; Egaña, J.T.; Núñez, M.T.; Maccioni, R.B.; González-Billault, C. Oxidative stress promotes tau
dephosphorylation in neuronal cells: The roles of cdk5 and PP1. Free Radic. Biol. Med. 2004, 36, 1393–1402.
[CrossRef] [PubMed]
92. Kang, S.W.; Kim, S.J.; Kim, M.S. Oxidative stress with tau hyperphosphorylation in memory impaired
1,2-diacetylbenzene-treated mice. Toxicol. Lett. 2017, 279, 53–59. [CrossRef] [PubMed]
93. De Vos, A.; Bynens, T.; Rosseels, J.; Coun, C.; Ring, J.; Madeo, F.; Galas, M.-C.; Winderickx, J.; Franssens, V.
The peptidyl prolyl cis/trans isomerase Pin1/Ess1 inhibits phosphorylation and toxicity of tau in a yeast
model for Alzheimer’s disease. AIMS Mol. Sci. 2015, 2, 144–160. [CrossRef]
Int. J. Mol. Sci. 2018, 19, 1947 19 of 26
94. Su, B.; Wang, X.; Lee, H.; Tabaton, M.; Perry, G.; Smith, M.A.; Zhu, X. Chronic oxidative stress causes
increased tau phosphorylation in M17 neuroblastoma cells. Neurosci. Lett. 2010, 468, 267–271. [CrossRef]
[PubMed]
95. Rosseels, J.; Van Den Brande, J.; Violet, M.; Jacobs, D.; Grognet, P.; Lopez, J.; Huvent, I.; Caldara, M.;
Swinnen, E.; Papegaey, A.; et al. Tau monoclonal antibody generation based on humanized yeast models:
Impact on tau oligomerization and diagnostics. J. Biol. Chem. 2015, 290, 4059–4074. [CrossRef] [PubMed]
96. Castillo-Carranza, D.L.; Gerson, J.E.; Sengupta, U.; Guerrero-Muñoz, M.J.; Lasagna-Reeves, C.A.; Kayed, R.
Specific Targeting of Tau Oligomers in HtauMice Prevents Cognitive Impairment and Tau Toxicity Following
Injection with Brain-Derived Tau Oligomeric Seeds. J. Alzheimer Dis. 2014, 40, S97–S111. [CrossRef] [PubMed]
97. Patterson, K.R.; Remmers, C.; Fu, Y.; Brooker, S.; Kanaan, N.M.; Vana, L.; Ward, S.; Reyes, J.F.; Philibert, K.;
Glucksman, M.J.; et al. Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease.
J. Biol. Chem. 2011, 286, 23063–23076. [CrossRef] [PubMed]
98. Pérez-Ruiz, E.; Decrop, D.; Ven, K.; Tripodi, L.; Leirs, K.; Rosseels, J.; van de Wouwer, M.; Geukens, N.;
De Vos, A.; Vanmechelen, E.; et al. Digital ELISA for the quantification of attomolar concentrations of
Alzheimer’s disease biomarker protein Tau in biological samples. Anal. Chim. Acta 2018, 1015, 74–81.
[CrossRef] [PubMed]
99. Giasson, B.I.; Forman, M.S.; Higuchi, M.; Golbe, L.I.; Graves, C.L.; Kotzbauer, P.T.; Trojanowski, J.Q.;
Lee, V.M.Y. Initiation and synergistic fibrillization of tau and alpha-synuctein. Science 2003, 300, 636–640.
[CrossRef] [PubMed]
100. Jensen, P.H.; Hager, H.; Nielsen, M.S.; Hojrup, P.; Gliemann, J.; Jakes, R. alpha-synuclein binds to Tau and
stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. J. Biol. Chem.
1999, 274, 25481–25489. [CrossRef] [PubMed]
101. Duka, T.; Rusnak, M.; Drolet, R.E.; Duka, V.; Wersinger, C.; Goudreau, J.L.; Sidhu, A. Alpha-Synuclein
Induces Hyperphosphorylation of Au in the Mptp Model of Parkinsonism. FASEB J. 2006, 20, 2302–2312.
[CrossRef] [PubMed]
102. Waxman, E.A.; Giasson, B.I. Induction of Intracellular Tau Aggregation Is Promoted by α-Synuclein Seeds
and Provides Novel Insights into the Hyperphosphorylation of Tau. J. Neurosci. 2011, 31, 7604–7618.
[CrossRef] [PubMed]
103. Frasier, M.; Walzer, M.; McCarthy, L.; Magnuson, D.; Lee, J.M.; Haas, C.; Kahle, P.; Wolozin, B. Tau
phosphorylation increases in symptomatic mice overexpressing A30P α-synuclein. Exp. Neurol. 2005,
192, 274–287. [CrossRef] [PubMed]
104. Zabrocki, P.; Pellens, K.; Vanhelmont, T.; Vandebroek, T.; Griffioen, G.; Wera, S.; Van Leuven, F.; Winderickx, J.
Characterization of α-synuclein aggregation and synergistic toxicity with protein tau in yeast. FEBS J. 2005,
272, 1386–1400. [CrossRef] [PubMed]
105. Ciaccioli, G.; Martins, A.; Rodrigues, C.; Vieira, H.; Calado, P. A powerful yeast model to investigate the
synergistic interaction of α-synuclein and tau in neurodegeneration. PLoS ONE 2013, 8, e55848. [CrossRef]
[PubMed]
106. Hoffman, C.S.; Wood, V.; Fantes, P.A. An Ancient Yeast for Young Geneticists: A Primer on the
Schizosaccharomyces pombe Model System. Genetics 2015, 201, 403–423. [CrossRef] [PubMed]
107. Balasubramanian, M.K.; Bi, E.; Glotzer, M. Comparative analysis of cytokinesis in budding yeast, fission
yeast and animal cells. Curr. Biol. 2004, 14, R806–R818. [CrossRef] [PubMed]
108. Humphrey, T.; Pearce, A. Cell cycle molecules and mechanisms of the budding and fission yeasts.
Methods Mol. Biol. 2005, 296, 3–29. [PubMed]
109. Heinisch, J.J.; Brandt, R. Signaling pathways and posttranslational modifications of tau in Alzheimer’s
disease: The humanization of yeast cells. Microb. Cell 2016, 3, 135–146. [CrossRef] [PubMed]
110. Rodicio, R.; Heinisch, J.J. Yeast on the milky way: Genetics, physiology and biotechnology of Kluyveromyces
lactis. Yeast 2013, 30, 165–177. [CrossRef] [PubMed]
111. Barnard, E.; McFerran, N.V.; Trudgett, A.; Nelson, J.; Timson, D.J. Development and implementation of
split-GFP-based bimolecular fluorescence complementation (BiFC) assays in yeast. Biochem. Soc. Trans. 2008,
36, 479–482. [CrossRef] [PubMed]
112. Cabantous, S.; Nguyen, H.B.; Pedelacq, J.D.; Koraïchi, F.; Chaudhary, A.; Ganguly, K.; Lockard, M.A.;
Favre, G.; Terwilliger, T.C.; Waldo, G.S. A new protein-protein interaction sensor based on tripartite split-GFP
association. Sci. Rep. 2013, 3, 02854. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 1947 20 of 26
113. Cabantous, S.; Terwilliger, T.C.; Waldo, G.S. Protein tagging and detection with engineered self-assembling
fragments of green fluorescent protein. Nat. Biotechnol. 2005, 23, 102–107. [CrossRef] [PubMed]
114. Cabantous, S.; Waldo, G.S. In vivo and in vitro protein solubility assays using split GFP. Nat. Methods 2006,
3, 845–854. [CrossRef] [PubMed]
115. Foglieni, C.; Papin, S.; Salvadè, A.; Afroz, T.; Pinton, S.; Pedrioli, G.; Ulrich, G.; Polymenidou, M.; Paganetti, P.
Split GFP technologies to structurally characterize and quantify functional biomolecular interactions of
FTD-related proteins. Sci. Rep. 2017, 7, 14013. [CrossRef] [PubMed]
116. Priller, C.; Bauer, T.; Mitteregger, G.; Krebs, B.; Kretzschmar, H.A.; Herms, J. Synapse Formation and Function
Is Modulated by the Amyloid Precursor Protein. J. Neurosci. 2006, 26, 7212–7221. [CrossRef] [PubMed]
117. Turner, P.R.; O’Connor, K.; Tate, W.P.; Abraham, W.C. Roles of amyloid precursor protein and its fragments
in regulating neural activity, plasticity and memory. Prog. Neurobiol. 2003, 70, 1–32. [CrossRef]
118. Duce, J.A.; Tsatsanis, A.; Cater, M.A.; James, S.A.; Robb, E.; Wikhe, K.; Leong, S.L.; Perez, K.; Johanssen, T.;
Greenough, M.A.; et al. Iron-Export Ferroxidase Activity of β-Amyloid Precursor Protein Is Inhibited by
Zinc in Alzheimer’s Disease. Cell 2010, 142, 857–867. [CrossRef] [PubMed]
119. Chen, G.; Xu, T.; Yan, Y.; Zhou, Y.; Jiang, Y.; Melcher, K.; Xu, H.E. Amyloid beta: Structure, biology and
structure-based therapeutic development. Acta Pharmacol. Sin. 2017, 38, 1205–1235. [CrossRef] [PubMed]
120. Haass, C.; Koo, E.H.; Mellon, A.; Hung, A.Y.; Selkoe, D.J. Targeting of cell-surface β-amyloid precursor
protein to lysosomes: Alternative processing into amyloid-bearing fragments. Nature 1992, 357, 500–503.
[CrossRef] [PubMed]
121. Joshi, G.; Wang, Y. Golgi defects enhance APP amyloidogenic processing in Alzheimer’s disease. BioEssays
2015, 37, 240–247. [CrossRef] [PubMed]
122. Olsson, F.; Schmidt, S.; Althoff, V.; Munter, L.M.; Jin, S.; Rosqvist, S.; Lendahl, U.; Multhaup, G.; Lundkvist, J.
Characterization of Intermediate Steps in Amyloid Beta (Aβ) Production under Near-native Conditions.
J. Biol. Chem. 2014, 289, 1540–1550. [CrossRef] [PubMed]
123. Takami, M.; Nagashima, Y.; Sano, Y.; Ishihara, S.; Morishima-Kawashima, M.; Funamoto, S.; Ihara, Y.
γ-Secretase: Successive Tripeptide and Tetrapeptide Release from the Transmembrane Domain of β-Carboxyl
Terminal Fragment. J. Neurosci. 2009, 29, 13042–13052. [CrossRef] [PubMed]
124. Wolfe, M.S. Inhibition and modulation of γ-secretase for Alzheimer’s disease. Neurotherapeutics 2008, 5,
391–398. [CrossRef] [PubMed]
125. Hensley, K.; Carney, J.M.; Mattson, M.P.; Aksenova, M.; Harris, M.; Wu, J.F.; Floyd, R.A.; Butterfield, D.A.
A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide:
Relevance to Alzheimer disease. Proc. Natl. Acad. Sci. USA 1994, 91, 3270–3274. [CrossRef] [PubMed]
126. .Benzinger, T.L.; Gregory, D.M.; Burkoth, T.S.; Miller-Auer, H.; Lynn, D.G.; Botto, R.E.; Meredith, S.C.
Propagating structure of Alzheimer’s beta-amyloid(10-35) is parallel beta-sheet with residues in exact
register. Proc. Natl. Acad. Sci. USA 1998, 95, 13407–13412. [CrossRef] [PubMed]
127. Yu, L.; Edalji, R.; Harlan, J.E.; Holzman, T.F.; Lopez, A.P.; Labkovsky, B.; Hillen, H.; Barghorn, S.; Ebert, U.;
Richardson, P.L.; et al. Structural Characterization of a Soluble Amyloid β-Peptide Oligomer. Biochemistry
2009, 48, 1870–1877. [CrossRef] [PubMed]
128. Haass, C.; Schlossmacher, M.G.; Hung, A.Y.; Vigo-Pelfrey, C.; Mellon, A.; Ostaszewski, B.L.; Lieberburg, I.;
Koo, E.H.; Schenk, D.; Teplow, D.B.; et al. Amyloid β-peptide is produced by cultured cells during normal
metabolism. Nature 1992, 359, 322–325. [CrossRef] [PubMed]
129. Terry, R.D.; Masliah, E.; Salmon, D.P.; Butters, N.; DeTeresa, R.; Hill, R.; Hansen, L.A.; Katzman, R. Physical
basis of cognitive alterations in alzheimer’s disease: Synapse loss is the major correlate of cognitive
impairment. Ann. Neurol. 1991, 30, 572–580. [CrossRef] [PubMed]
130. Masliah, E.; Terry, R.D.; Alford, M.; DeTeresa, R.; Hansen, L.A. Cortical and subcortical patterns of
synaptophysinlike immunoreactivity in Alzheimer’s disease. Am. J. Pathol. 1991, 138, 235–246. [PubMed]
131. Masliah, E.; Achim, C.L.; Ge, N.; DeTeresa, R.; Terry, R.D.; Wiley, C.A. Spectrum of human immunodeficiency
virus-associated neocortical damage. Ann. Neurol. 1992, 32, 321–329. [CrossRef] [PubMed]
132. Mucke, L.; Masliah, E.; Yu, G.Q.; Mallory, M.; Rockenstein, E.M.; Tatsuno, G.; Hu, K.; Kholodenko, D.;
Johnson-Wood, K.; McConlogue, L. High-level neuronal expression of abeta 1-42 in wild-type human
amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J. Neurosci. 2000, 20,
4050–4058. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 1947 21 of 26
133. Hsia, A.Y.; Masliah, E.; McConlogue, L.; Yu, G.Q.; Tatsuno, G.; Hu, K.; Kholodenko, D.; Malenka, R.C.;
Nicoll, R.A.; Mucke, L. Plaque-independent disruption of neural circuits in Alzheimer’s disease mouse
models. Proc. Natl. Acad. Sci. USA 1999, 96, 3228–3233. [CrossRef] [PubMed]
134. Canevari, L.; Abramov, A.Y.; Duchen, M.R. Toxicity of amyloid beta peptide: Tales of calcium, mitochondria,
and oxidative stress. Neurochem. Res. 2004, 29, 637–650. [CrossRef] [PubMed]
135. Mattson, M.P. Pathways towards and away from Alzheimer’s disease. Nature 2004, 430, 631–639. [CrossRef]
[PubMed]
136. Weggen, S.; Eriksen, J.L.; Das, P.; Sagi, S.A.; Wang, R.; Pietrzik, C.U.; Findlay, K.A.; Smith, T.E.; Murphy, M.P.;
Bulter, T.; et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity.
Nature 2001, 414, 212–216. [CrossRef] [PubMed]
137. Neniskyte, U.; Neher, J.J.; Brown, G.C. Neuronal Death Induced by Nanomolar Amyloid β Is Mediated by
Primary Phagocytosis of Neurons by Microglia. J. Biol. Chem. 2011, 286, 39904–39913. [CrossRef] [PubMed]
138. Heneka, M.T.; Golenbock, D.T.; Latz, E. Innate immunity in Alzheimer’s disease. Nat. Immunol. 2015, 16,
229–236. [CrossRef] [PubMed]
139. Iwata, N.; Tsubuki, S.; Takaki, Y.; Watanabe, K.; Sekiguchi, M.; Hosoki, E.; Kawashima-Morishima, M.;
Lee, H.-J.; Hama, E.; Sekine-Aizawa, Y.; et al. Identification of the major Aβ1–42-degrading catabolic pathway
in brain parenchyma: Suppression leads to biochemical and pathological deposition. Nat. Med. 2000, 6,
143–150. [CrossRef] [PubMed]
140. Iwata, N.; Tsubuki, S.; Takaki, Y.; Shirotani, K.; Lu, B.; Gerard, N.P.; Gerard, C.; Hama, E.; Lee, H.J.; Saido, T.C.
Metabolic Regulation of Brain Abeta by Neprilysin. Science 2001, 292, 1550–1552. [CrossRef] [PubMed]
141. Selkoe, D.J. Clearing the brain’s amyloid cobwebs. Neuron 2001, 32, 177–180. [CrossRef]
142. DeMattos, R.B.; Bales, K.R.; Cummins, D.J.; Dodart, J.-C.; Paul, S.M.; Holtzman, D.M. Peripheral anti-Aβ
antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of
Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 2001, 98, 8850–8855. [CrossRef] [PubMed]
143. Zlokovic, B.V.; Yamada, S.; Holtzman, D.; Ghiso, J.; Frangione, B. Clearance of amyloid beta-peptide from
brain: Transport or metabolism? Nat. Med. 2000, 6, 718. [CrossRef] [PubMed]
144. Martel, C.L.; Mackic, J.B.; Matsubara, E.; Governale, S.; Miguel, C.; Miao, W.; McComb, J.G.; Frangione, B.;
Ghiso, J.; Zlokovic, B. V Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary
sequestration and blood-brain barrier transport of circulating Alzheimer’s amyloid beta. J. Neurochem. 1997,
69, 1995–2004. [CrossRef] [PubMed]
145. Ghersi-Egea, J.F.; Gorevic, P.D.; Ghiso, J.; Frangione, B.; Patlak, C.S.; Fenstermacher, J.D. Fate of cerebrospinal
fluid-borne amyloid beta-peptide: Rapid clearance into blood and appreciable accumulation by cerebral
arteries. J. Neurochem. 1996, 67, 880–883. [CrossRef] [PubMed]
146. Maness, L.M.; Banks, W.A.; Podlisny, M.B.; Selkoe, D.J.; Kastin, A.J. Passage of human amyloid beta-protein
1–40 across the murine blood-brain barrier. Life Sci. 1994, 55, 1643–1650. [CrossRef]
147. Zlokovic, B.V.; Martel, C.L.; Mackic, J.B.; Matsubara, E.; Wisniewski, T.; Mccomb, J.G.; Frangione, B.; Ghiso, J.
Brain Uptake of Circulating Apolipoproteins J and E Complexed to Alzheimer′s Amyloid β. Biochem. Biophys.
Res. Commun. 1994, 205, 1431–1437. [CrossRef] [PubMed]
148. Hardy, J.; Selkoe, D.J. The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road
to Therapeutics. Science 2002, 297, 353–356. [CrossRef] [PubMed]
149. Tanzi, R.E.; Moir, R.D.; Wagner, S.L. Clearance of Alzheimer’s Aβ Peptide. Neuron 2004, 43, 605–608.
[CrossRef] [PubMed]
150. Wyss-Coray, T.; Loike, J.D.; Brionne, T.C.; Lu, E.; Anankov, R.; Yan, F.; Silverstein, S.C.; Husemann, J. Adult
mouse astrocytes degrade amyloid-β in vitro and in situ. Nat. Med. 2003, 9, 453–457. [CrossRef] [PubMed]
151. Koistinaho, M.; Lin, S.; Wu, X.; Esterman, M.; Koger, D.; Hanson, J.; Higgs, R.; Liu, F.; Malkani, S.;
Bales, K.R.; et al. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited
amyloid-β peptides. Nat. Med. 2004, 10, 719–726. [CrossRef] [PubMed]
152. Zlokovic, B.V.; Deane, R.; Sallstrom, J.; Chow, N.; Miano, J.M. Neurovascular pathways and Alzheimer
amyloid beta-peptide. Brain Pathol. 2005, 15, 78–83. [CrossRef] [PubMed]
153. Cataldo, A.M.; Hamilton, D.J.; Barnett, J.L.; Paskevich, P.A.; Nixon, R.A. Properties of the
endosomal-lysosomal system in the human central nervous system: Disturbances mark most neurons
in populations at risk to degenerate in Alzheimer’s disease. J. Neurosci. 1996, 16, 186–199. [CrossRef]
[PubMed]
Int. J. Mol. Sci. 2018, 19, 1947 22 of 26
154. Zhang, H.; Komano, H.; Fuller, R.S.; Gandy, S.E.; Frail, D.E. Proteolytic processing and secretion of human
beta-amyloid precursor protein in yeast. Evidence for a yeast secretase activity. J. Biol. Chem. 1994, 269,
27799–27802. [PubMed]
155. Hines, V.; Zhang, W.; Ramakrishna, N.; Styles, J.; Mehta, P.; Kim, K.S.; Innis, M.; Miller, D.L. The expression
and processing of human beta-amyloid peptide precursors in Saccharomyces cerevisiae: Evidence for a novel
endopeptidase in the yeast secretory system. Cell. Mol. Biol. Res. 1994, 40, 273–284. [PubMed]
156. Zhang, W.; Espinoza, D.; Hines, V.; Innis, M.; Mehta, P.; Miller, D.L. Characterization of β-amyloid peptide
precursor processing by the yeast Yap3 and Mkc7 proteases. Biochim. Biophys. Acta Mol. Cell Res. 1997, 1359,
110–122. [CrossRef]
157. Komano, H.; Seeger, M.; Gandy, S.; Wang, G.T.; Krafft, G.A.; Fuller, R.S. Involvement of cell surface
glycosyl-phosphatidylinositol-linked aspartyl proteases in alpha-secretase-type cleavage and ectodomain
solubilization of human Alzheimer beta-amyloid precursor protein in yeast. J. Biol. Chem. 1998, 273,
31648–31651. [CrossRef] [PubMed]
158. Edbauer, D.; Winkler, E.; Regula, J.T.; Pesold, B.; Steiner, H.; Haass, C. Reconstitution of γ-secretase activity.
Nat. Cell Biol. 2003, 5, 486–488. [CrossRef] [PubMed]
159. Yagishita, S.; Futai, E.; Ishiura, S. In vitro reconstitution of gamma-secretase activity using yeast microsomes.
Biochem. Biophys. Res. Commun. 2008, 377, 141–145. [CrossRef] [PubMed]
160. Yonemura, Y.; Futai, E.; Yagishita, S.; Suo, S.; Tomita, T.; Iwatsubo, T.; Ishiura, S. Comparison of presenilin
1 and presenilin 2 γ-secretase activities using a yeast reconstitution system. J. Biol. Chem. 2011, 286,
44569–44575. [CrossRef] [PubMed]
161. Yonemura, Y.; Futai, E.; Yagishita, S.; Kaether, C.; Ishiura, S. Specific combinations of presenilins and Aph1s
affect the substrate specificity and activity of γ-secretase. Biochem. Biophys. Res. Commun. 2016, 478,
1751–1757. [CrossRef] [PubMed]
162. Futai, E.; Yagishita, S.; Ishiura, S. Nicastrin is dispensable for gamma-secretase protease activity in the
presence of specific presenilin mutations. J. Biol. Chem. 2009, 284, 13013–13022. [CrossRef] [PubMed]
163. Wickner, R.B.; Edskes, H.K.; Kryndushkin, D.; McGlinchey, R.; Bateman, D.; Kelly, A. Prion diseases of yeast:
Amyloid structure and biology. Semin. Cell Dev. Biol. 2011, 22, 469–475. [CrossRef] [PubMed]
164. Bagriantsev, S.; Liebman, S. Modulation of Abeta42 low-n oligomerization using a novel yeast reporter
system. BMC Biol. 2006, 4, 32. [CrossRef] [PubMed]
165. von der Haar, T.; Jossé, L.; Wright, P.; Zenthon, J.; Tuite, M.F. Development of a novel yeast cell-based system
for studying the aggregation of Alzheimer’s disease-associated Abeta peptides in vivo. Neurodegener. Dis.
2007, 4, 136–147. [CrossRef] [PubMed]
166. Caine, J.; Sankovich, S.; Antony, H.; Waddington, L.; Macreadie, P.; Varghese, J.; Macreadie, I. Alzheimer’s
Abeta fused to green fluorescent protein induces growth stress and a heat shock response. FEMS Yeast Res.
2007, 7, 1230–1236. [CrossRef] [PubMed]
167. Hamos, J.E.; Oblas, B.; Pulaski-Salo, D.; Welch, W.J.; Bole, D.G.; Drachman, D.A. Expression of heat shock
proteins in Alzheimer’s disease. Neurology 1991, 41, 345–350. [CrossRef] [PubMed]
168. Macreadie, I.; Lotfi-Miri, M.; Mohotti, S.; Shapira, D.; Bennett, L.; Varghese, J. Validation of folate in
a convenient yeast assay suited for identification of inhibitors of Alzheimer’s amyloid-beta aggregation.
J. Alzheimer’s Dis. 2008, 15, 391–396. [CrossRef]
169. Rajasekhar, K.; Suresh, S.N.; Manjithaya, R.; Govindaraju, T. Rationally Designed PeptidomimeticModulators
of Aβ Toxicity in Alzheimer’s Disease. Sci. Rep. 2015, 5, 8139. [CrossRef] [PubMed]
170. Bharadwaj, P.R.; Verdile, G.; Barr, R.K.; Gupta, V.; Steele, J.W.; Lachenmayer, M.L.; Yue, Z.; Ehrlich, M.E.;
Petsko, G.; Ju, S.; et al. Latrepirdine (dimebon) enhances autophagy and reduces intracellular GFP-Aβ42
levels in yeast. J. Alzheimer’s Dis. 2012, 32, 949–967. [CrossRef] [PubMed]
171. .Nixon, R.A.; Wegiel, J.; Kumar, A.; Yu, W.H.; Peterhoff, C.; Cataldo, A.; Cuervo, A.M. Extensive involvement
of autophagy in Alzheimer disease: An immuno-electron microscopy study. J. Neuropathol. Exp. Neurol. 2005,
64, 113–122. [CrossRef] [PubMed]
172. Yu, W.H.; Cuervo, A.M.; Kumar, A.; Peterhoff, C.M.; Schmidt, S.D.; Lee, J.-H.; Mohan, P.S.; Mercken, M.;
Farmery, M.R.; Tjernberg, L.O.; et al. Macroautophagy—A novel β-amyloid peptide-generating pathway
activated in Alzheimer’s disease. J. Cell Biol. 2005, 171, 87–98. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 1947 23 of 26
173. Lee, J.-H.; Yu, W.H.; Kumar, A.; Lee, S.; Mohan, P.S.; Peterhoff, C.M.; Wolfe, D.M.; Martinez-Vicente, M.;
Massey, A.C.; Sovak, G.; et al. Lysosomal Proteolysis and Autophagy Require Presenilin 1 and Are Disrupted
by Alzheimer-Related PS1 Mutations. Cell 2010, 141, 1146–1158. [CrossRef] [PubMed]
174. Steele, J.W.; Lachenmayer, M.L.; Ju, S.; Stock, A.; Liken, J.; Kim, S.H.; Delgado, L.M.; Alfaro, I.E.;
Bernales, S.; Verdile, G.; et al. Latrepirdine improves cognition and arrests progression of neuropathology in
an Alzheimer’s mouse model. Mol. Psychiatry 2013, 18, 889–897. [CrossRef] [PubMed]
175. Matlack, K.E.S.; Tardiff, D.F.; Narayan, P.; Hamamichi, S.; Caldwell, K.A.; Caldwell, G.A.; Lindquist, S.
Clioquinol promotes the degradation of metal-dependent amyloid-β (Aβ) oligomers to restore endocytosis
and ameliorate Aβ toxicity. Proc. Natl. Acad. Sci. USA 2014, 111, 4013–4018. [CrossRef] [PubMed]
176. Tardiff, D.F.; Brown, L.E.; Yan, X.; Trilles, R.; Jui, N.T.; Barrasa, M.I.; Caldwell, K.A.; Caldwell, G.A.;
Schaus, S.E.; Lindquist, S. Dihydropyrimidine-Thiones and Clioquinol Synergize To Target β-Amyloid
Cellular Pathologies through a Metal-Dependent Mechanism. ACS Chem. Neurosci. 2017, 8, 2039–2055.
[CrossRef] [PubMed]
177. Cherny, R.A.; Atwood, C.S.; Xilinas, M.E.; Gray, D.N.; Jones, W.D.; McLean, C.A.; Barnham, K.J.; Volitakis, I.;
Fraser, F.W.; Kim, Y.-S.; et al. Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits
β-Amyloid Accumulation in Alzheimer’s Disease Transgenic Mice. Neuron 2001, 30, 665–676. [CrossRef]
178. Adlard, P.A.; Cherny, R.A.; Finkelstein, D.I.; Gautier, E.; Robb, E.; Cortes, M.; Volitakis, I.; Liu, X.; Smith, J.P.;
Perez, K.; et al. Rapid Restoration of Cognition in Alzheimer’s Transgenic Mice with 8-Hydroxy Quinoline
Analogs Is Associated with Decreased Interstitial Aβ. Neuron 2008, 59, 43–55. [CrossRef] [PubMed]
179. Lannfelt, L.; Blennow, K.; Zetterberg, H.; Batsman, S.; Ames, D.; Harrison, J.; Masters, C.L.; Targum, S.;
Bush, A.I.; Murdoch, R.; et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as
a modifying therapy for Alzheimer’s disease: A phase IIa, double-blind, randomised, placebo-controlled
trial. Lancet Neurol. 2008, 7, 779–786. [CrossRef]
180. LaFerla, F.M.; Green, K.N.; Oddo, S. Intracellular amyloid-β in Alzheimer’s disease. Nat. Rev. Neurosci. 2007,
8, 499–509. [CrossRef] [PubMed]
181. .Treusch, S.; Hamamichi, S.; Goodman, J.L.; Matlack, K.E.S.; Chung, C.Y.; Baru, V.; Shulman, J.M.; Parrado, A.;
Bevis, B.J.; Valastyan, J.S.; et al. Functional links between Aβ toxicity, endocytic trafficking, and Alzheimer’s
disease risk factors in yeast. Science 2011, 334, 1241–1245. [CrossRef] [PubMed]
182. D’Angelo, F.; Vignaud, H.; Di Martino, J.; Salin, B.; Devin, A.; Cullin, C.; Marchal, C. A yeast model
for amyloid-β aggregation exemplifies the role of membrane trafficking and PICALM in cytotoxicity.
Dis. Model. Mech. 2013, 6, 206–216. [CrossRef] [PubMed]
183. Park, S.-K.; Ratia, K.; Ba, M.; Valencik, M.; Liebman, S.W. Inhibition of Aβ42 oligomerization in yeast by
a PICALM ortholog and certain FDA approved drugs. Microb. Cell 2016, 3, 53–64. [CrossRef] [PubMed]
184. Chen, X.; Petranovic, D. Amyloid-β peptide-induced cytotoxicity and mitochondrial dysfunction in yeast.
FEMS Yeast Res. 2015, 15, fov061. [CrossRef] [PubMed]
185. Fukui, H.; Moraes, C.T. The mitochondrial impairment, oxidative stress and neurodegeneration connection:
Reality or just an attractive hypothesis? Trends Neurosci. 2008, 31, 251–256. [CrossRef] [PubMed]
186. Chen, X.; Bisschops, M.M.M.; Agarwal, N.R.; Ji, B.; Shanmugavel, K.P.; Petranovic, D. Interplay of Energetics
and ER Stress Exacerbates Alzheimer’s Amyloid-β (Aβ) Toxicity in Yeast. Front. Mol. Neurosci. 2017, 10, 232.
[CrossRef] [PubMed]
187. Stahl, A.; Moberg, P.; Ytterberg, J.; Panfilov, O.; Brockenhuus Von Lowenhielm, H.; Nilsson, F.; Glaser, E.
Isolation and identification of a novel mitochondrial metalloprotease (PreP) that degrades targeting
presequences in plants. J. Biol. Chem. 2002, 277, 41931–41939. [CrossRef] [PubMed]
188. Alikhani, N.; Berglund, A.-K.; Engmann, T.; Spånning, E.; Vögtle, F.-N.; Pavlov, P.; Meisinger, C.; Langer, T.;
Glaser, E. Targeting Capacity and Conservation of PreP Homologues Localization in Mitochondria of
Different Species. J. Mol. Biol. 2011, 410, 400–410. [CrossRef] [PubMed]
189. Alikhani, N.; Guo, L.; Yan, S.; Du, H.; Pinho, C.M.; Chen, J.X.; Glaser, E.; Yan, S.S. Decreased proteolytic
activity of the mitochondrial amyloid-β degrading enzyme, PreP peptidasome, in Alzheimer’s disease brain
mitochondria. J. Alzheimer’s Dis. 2011, 27, 75–87. [CrossRef] [PubMed]
190. Teixeira, P.F.; Glaser, E. Processing peptidases in mitochondria and chloroplasts. Biochim. Biophys. Acta-Mol.
Cell Res. 2013, 1833, 360–370. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 1947 24 of 26
191. Mossmann, D.; Vögtle, F.-N.; Taskin, A.A.; Teixeira, P.F.; Ring, J.; Burkhart, J.M.; Burger, N.; Pinho, C.M.;
Tadic, J.; Loreth, D.; et al. Amyloid-β Peptide Induces Mitochondrial Dysfunction by Inhibition of Preprotein
Maturation. Cell Metab. 2014, 20, 662–669. [CrossRef] [PubMed]
192. Brunetti, D.; Torsvik, J.; Dallabona, C.; Teixeira, P.; Sztromwasser, P.; Fernandez-Vizarra, E.; Cerutti, R.;
Reyes, A.; Preziuso, C.; D’Amati, G.; et al. Defective PITRM1 mitochondrial peptidase is associated with A
amyloidotic neurodegeneration. EMBOMol. Med. 2016, 8, 176–190. [CrossRef] [PubMed]
193. Cenini, G.; Rub, C.; Bruderek, M.; Voos, W. Amyloid β-peptides interfere with mitochondrial preprotein
import competence by a coaggregation process. Mol. Biol. Cell 2016, 27, 3257–3272. [CrossRef] [PubMed]
194. Bharadwaj, P.; Waddington, L.; Varghese, J.; Macreadie, I.G. A new method to measure cellular toxicity of
non-fibrillar and fibrillar Alzheimer’s Abeta using yeast. J. Alzheimer’s Dis. 2008, 13, 147–150. [CrossRef]
195. Dubey, A.K.; Bharadwaj, P.R.; Varghese, J.N.; Macreadie, I.G. Alzheimer’s Amyloid-β Rescues Yeast from
Hydroxide Toxicity. J. Alzheimer’s Dis. 2009, 18, 31–33. [CrossRef] [PubMed]
196. Liou, Y.-C.; Sun, A.; Ryo, A.; Zhou, X. Z.; Yu, Z.-X.; Huang, H.-K.; Uchida, T.; Bronson, R.; Bing, G.; Li, X.; et al.
Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature 2003, 424,
556–561. [CrossRef] [PubMed]
197. Kondo, A.; Albayram, O.; Zhou, X.Z.; Lu, K.P. Pin1 Knockout Mice: A Model for the Study of Tau Pathology
in Alzheimer’s Disease. Methods Mol Biol. 2017, 1523, 415–425. [PubMed]
198. van Leeuwen, F.W.; de Kleijn, D.P.; van den Hurk, H.H.; Neubauer, A.; Sonnemans, M.A.; Sluijs, J.A.;
Köycü, S.; Ramdjielal, R.D.; Salehi, A.; Martens, G.J.; et al. Frameshift mutants of beta amyloid precursor
protein and ubiquitin-B in Alzheimer’s and Down patients. Science 1998, 279, 242–247. [CrossRef] [PubMed]
199. Morishima-Kawashima, M.; Hasegawa, M.; Takio, K.; Suzuki, M.; Titani, K.; Ihara, Y. Ubiquitin is conjugated
with amino-terminally processed tau in paired helical filaments. Neuron 1993, 10, 1151–1160. [CrossRef]
200. Hilt, W.; Wolf, D.H. Proteasomes: Destruction as a programme. Trends Biochem. Sci. 1996, 21, 96–102.
[CrossRef]
201. van Tijn, P.; de Vrij, F.M.S.; Schuurman, K.G.; Dantuma, N.P.; Fischer, D.F.; van Leeuwen, F.W.; Hol, E.M.
Dose-dependent inhibition of proteasome activity by a mutant ubiquitin associated with neurodegenerative
disease. J. Cell Sci. 2007, 120, 1615–1623. [CrossRef] [PubMed]
202. Lindsten, K.; de Vrij, F.M.S.; Verhoef, L.G.G.C.; Fischer, D.F.; van Leeuwen, F.W.; Hol, E.M.; Masucci, M.G.;
Dantuma, N.P. Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation
substrate that blocks proteasomal degradation. J. Cell Biol. 2002, 157, 417–427. [CrossRef] [PubMed]
203. Braun, R.J.; Sommer, C.; Leibiger, C.; Gentier, R.J.G.; Dumit, V.I.; Paduch, K.; Eisenberg, T.; Habernig, L.;
Trausinger, G.; Magnes, C.; et al. Accumulation of Basic Amino Acids at Mitochondria Dictates the
Cytotoxicity of Aberrant Ubiquitin. Cell Rep. 2015, 10, 1557–1571. [CrossRef] [PubMed]
204. Tank, E.M.H.; True, H.L. Disease-Associated Mutant Ubiquitin Causes Proteasomal Impairment and
Enhances the Toxicity of Protein Aggregates. PLoS Genet. 2009, 5, e1000382. [CrossRef] [PubMed]
205. Krutauz, D.; Reis, N.; Nakasone, M.A.; Siman, P.; Zhang, D.; Kirkpatrick, D.S.; Gygi, S.P.; Brik, A.;
Fushman, D.; Glickman, M.H. Extended ubiquitin species are protein-based DUB inhibitors. Nat. Chem. Biol.
2014, 10, 664–670. [CrossRef] [PubMed]
206. De Vrij, F.M.S.; Sluijs, J.A.; Gregori, L.; Fischer, D.F.; Hermens, W.T.J.M.C.; Goldgaber, D.; Verhaagen, J.; Van
Leeuwen, F.W.; Hol, E.M. Mutant ubiquitin expressed in Alzheimer’s disease causes neuronal death. FASEB
J. 2001, 15, 2680–2688. [CrossRef] [PubMed]
207. Tan, Z.; Sun, X.; Hou, F.-S.; Oh, H.-W.; Hilgenberg, L.G.W.; Hol, E.M.; van Leeuwen, F.W.; Smith, M.A.;
O’Dowd, D.K.; Schreiber, S.S. Mutant ubiquitin found in Alzheimer’s disease causes neuritic beading of
mitochondria in association with neuronal degeneration. Cell Death Differ. 2007, 14, 1721–1732. [CrossRef]
[PubMed]
208. Braun, R.J. Ubiquitin-dependent proteolysis in yeast cells expressing neurotoxic proteins. Front. Mol. Neurosci.
2015, 8, 8. [CrossRef] [PubMed]
209. Colby, D.W.; Prusiner, S.B. Prions. Cold Spring Harb. Perspect. Biol. 2011, 3, a006833. [CrossRef] [PubMed]
210. Prusiner, S.B. Creutzfeldt-Jakob disease and scrapie prions. Alzheimer Dis. Assoc. Disord. 1989, 3, 52–78.
[CrossRef] [PubMed]
211. Safar, J.G. Molecular pathogenesis of sporadic prion diseases in man. Prion 2012, 6, 108–115. [CrossRef]
[PubMed]
Int. J. Mol. Sci. 2018, 19, 1947 25 of 26
212. Wickner, R.B.; Shewmaker, F.P.; Bateman, D.A.; Edskes, H.K.; Gorkovskiy, A.; Dayani, Y.; Bezsonov, E.E.
Yeast Prions: Structure, Biology, and Prion-Handling Systems. Microbiol. Mol. Biol. Rev. 2015, 79, 1–17.
[CrossRef] [PubMed]
213. Wickner, R.B.; Edskes, H.K.; Son, M.; Bezsonov, E.E.; DeWilde, M.; Ducatez, M. Yeast Prions Compared to
Functional Prions and Amyloids. J. Mol. Biol. 2018. [CrossRef] [PubMed]
214. Riek, R.; Saupe, S.J. The HET-S/s Prion Motif in the Control of Programmed Cell Death. Cold Spring Harb.
Perspect. Biol. 2016, 8, a023515. [CrossRef] [PubMed]
215. Coustou, V.; Deleu, C.; Saupe, S.; Begueret, J. The protein product of the het-s heterokaryon incompatibility
gene of the fungus Podospora anserina behaves as a prion analog. Proc. Natl. Acad. Sci. USA 1997, 94,
9773–9778. [CrossRef] [PubMed]
216. Wickner, R.B.; Bezsonov, E.E.; Son, M.; Ducatez, M.; DeWilde, M.; Edskes, H.K. Anti-Prion Systems in Yeast
and Inositol Polyphosphates. Biochemistry 2018, 57, 1285–1292. [CrossRef] [PubMed]
217. Wu, Y.-X.; Greene, L.E.; Masison, D.C.; Eisenberg, E. Curing of yeast [PSI+] prion by guanidine inactivation
of Hsp104 does not require cell division. Proc. Natl. Acad. Sci. USA 2005, 102, 12789–12794. [CrossRef]
[PubMed]
218. Wegrzyn, R.D.; Bapat, K.; Newnam, G.P.; Zink, A.D.; Chernoff, Y.O. Mechanism of prion loss after Hsp104
inactivation in yeast. Mol. Cell. Biol. 2001, 21, 4656–4669. [CrossRef] [PubMed]
219. Moriyama, H.; Edskes, H.K.; Wickner, R.B. [URE3] prion propagation in Saccharomyces cerevisiae:
Requirement for chaperone Hsp104 and curing by overexpressed chaperone Ydj1p. Mol. Cell. Biol. 2000, 20,
8916–8922. [CrossRef] [PubMed]
220. Kryndushkin, D.S.; Shewmaker, F.; Wickner, R.B. Curing of the [URE3] prion by Btn2p, a Batten
disease-related protein. EMBO J. 2008, 27, 2725–2735. [CrossRef] [PubMed]
221. Wickner, R.B.; Bezsonov, E.; Bateman, D.A. Normal levels of the antiprion proteins Btn2 and Cur1 cure
most newly formed [URE3] prion variants. Proc. Natl. Acad. Sci. USA 2014, 111, E2711–E2720. [CrossRef]
[PubMed]
222. O’Driscoll, J.; Clare, D.; Saibil, H. Prion aggregate structure in yeast cells is determined by the Hsp104-Hsp110
disaggregase machinery. J. Cell Biol. 2015, 211, 145–158. [CrossRef] [PubMed]
223. Romanova, N.V.; Chernoff, Y.O. Hsp104 and prion propagation. Protein Pept. Lett. 2009, 16, 598–605.
[CrossRef] [PubMed]
224. Mukherjee, A.; Soto, C. Prion-Like Protein Aggregates and Type 2 Diabetes. Cold Spring Harb. Perspect. Med.
2017, 7, a024315. [CrossRef] [PubMed]
225. Moore, R.C.; Xiang, F.; Monaghan, J.; Han, D.; Zhang, Z.; Edström, L.; Anvret, M.; Prusiner, S.B. Huntington
Disease Phenocopy Is a Familial Prion Disease. Am. J. Hum. Genet. 2001, 69, 1385–1388. [CrossRef] [PubMed]
226. Abbott, A. The red-hot debate about transmissible Alzheimer’s. Nature 2016, 531, 294–297. [CrossRef]
[PubMed]
227. Olsson, T.T.; Klementieva, O.; Gouras, G.K. Prion-like seeding and nucleation of intracellular amyloid-β.
Neurobiol. Dis. 2018, 113, 1–10. [CrossRef] [PubMed]
228. Lu, J.-X.; Qiang, W.; Yau, W.-M.; Schwieters, C.D.; Meredith, S.C.; Tycko, R. Molecular Structure of β-Amyloid
Fibrils in Alzheimer’s Disease Brain Tissue. Cell 2013, 154, 1257–1268. [CrossRef] [PubMed]
229. Coalier, K.A.; Paranjape, G.S.; Karki, S.; Nichols, M.R. Stability of early-stage amyloid-β(1–42) aggregation
species. Biochim. Biophys. Acta Proteins Proteom. 2013, 1834, 65–70. [CrossRef] [PubMed]
230. Holmes, B.B.; Diamond, M.I. Prion-like properties of Tau protein: The importance of extracellular Tau as
a therapeutic target. J. Biol. Chem. 2014, 289, 19855–19861. [CrossRef] [PubMed]
231. .Kaufman, S.K.; Sanders, D.W.; Thomas, T.L.; Ruchinskas, A.J.; Vaquer-Alicea, J.; Sharma, A.M.; Miller, T.M.;
Diamond, M.I. Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional
Vulnerability In Vivo. Neuron 2016, 92, 796–812. [CrossRef] [PubMed]
232. Fruhmann, G.; Seynnaeve, D.; Zheng, J.; Ven, K.; Molenberghs, S.; Wilms, T.; Liu, B.; Winderickx, J.;
Franssens, V. Yeast buddies helping to unravel the complexity of neurodegenerative disorders.
Mech. Ageing Dev. 2017, 161, 288–305. [CrossRef] [PubMed]
233. Brachmann, A.; Toombs, J.A.; Ross, E.D. Reporter assay systems for [URE3] detection and analysis. Methods
2006, 39, 35–42. [CrossRef] [PubMed]
234. Schlumpberger, M.; Prusiner, S.B.; Herskowitz, I. Induction of distinct [URE3] yeast prion strains.
Mol. Cell. Biol. 2001, 21, 7035–7046. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 1947 26 of 26
235. Newby, G.A.; Kiriakov, S.; Hallacli, E.; Kayatekin, C.; Tsvetkov, P.; Mancuso, C.P.; Bonner, J.M.; Hesse, W.R.;
Chakrabortee, S.; Manogaran, A.L.; et al. A Genetic Tool to Track Protein Aggregates and Control Prion
Inheritance. Cell 2017, 171, 966–979.e18. [CrossRef] [PubMed]
236. Chun, W.; Waldo, G.S.; Johnson, G.V.W. Split GFP complementation assay: a novel approach to quantitatively
measure aggregation of tau in situ: Effects of GSK3β activation and caspase 3 cleavage. J. Neurochem. 2007,
103, 2529–2539. [CrossRef] [PubMed]
237. Zhao, L.; Yang, Q.; Zheng, J.; Zhu, X.; Hao, X.; Song, J.; Lebacq, T.; Franssens, V.; Winderickx, J.;
Nystrom, T.; et al. A genome-wide imaging-based screening to identify genes involved in synphilin-1
inclusion formation in Saccharomyces cerevisiae. Sci. Rep. 2016, 6, 30134. [CrossRef] [PubMed]
238. Yu, Y.; Li, Y.; Zhang, Y. Screening of APP interaction proteins by DUALmembrane yeast two-hybrid system.
Int. J. Clin. Exp. Pathol. 2015, 8, 2802–2808. [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
